156 results on '"Dimou M"'
Search Results
2. P1646: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN PATIENTS OLDER THAN 75 YEARS: REAL WORLD DATA FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY
- Author
-
Pontikoglou, C., primary, Matheakakis, A., additional, Stavroulaki, E., additional, Chatzilygeroudi, T., additional, Kourakli, A., additional, Symeonidis, A., additional, Dimou, M., additional, Panayiotidis, P., additional, Drakos, G., additional, Koudouna, A., additional, Galanopoulos, A., additional, Kaliafentaki, V., additional, Kanellou, P., additional, Liapi, D., additional, Tsirakis, G., additional, Kolovou, A., additional, Gavriilaki, E., additional, Syrigou, A., additional, Sakellari, I., additional, Chatzileontiadou, S., additional, Papaioannou, M., additional, Bobola, M., additional, Diamantopoulos, P., additional, Mantzourani, M., additional, Viniou, N.-A., additional, Dellatola, M., additional, Souravla, A., additional, Pagoni, M., additional, Megalakaki, A., additional, Christodoulou, I., additional, Vlachaki, E., additional, Giannouli, S., additional, Gkalea, V., additional, Matsouka, C., additional, Kotsianidis, I., additional, Vassilopoulos, G., additional, Protopappa, M., additional, Hatzimichael, E., additional, Zikos, P., additional, Chalkiadakis, G. N., additional, and Papadaki, H. A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Is diet partly responsible for differences in COVID-19 death rates between and within countries?
- Author
-
Bousquet J., Anto J. M., Iaccarino G., Czarlewski W., Haahtela T., Anto A., Akdis C. A., Blain H., Canonica G. W., Cardona V., Cruz A. A., Illario M., Ivancevich J. C., Jutel M., Klimek L., Kuna P., Laune D., Larenas-Linnemann D., Mullol J., Papadopoulos N. G., Pfaar O., Samolinski B., Valiulis A., Yorgancioglu A., Zuberbier T., Abdul Latiff A. H., Abdullah B., Aberer W., Abusada N., Adcock I., Afani A., Agache I., Aggelidis X., Agustin J., Akdis C., Akdis M., Al-Ahmad M., Al-Zahab Bassam A., Aldrey-Palacios O., Alvarez Cuesta E., Alzaabi A., Amad S., Ambrocio G., Annesi-Maesano I., Ansotegui I., Anto J., Arshad H., Artesani M. C., Asayag E., Avolio F., Azhari K., Baiardini I., Bajrovic N., Bakakos P., Bakeyala Mongono S., Balotro-Torres C., Barba S., Barbara C., Barbosa E., Barreto B., Bartra J., Bateman E. D., Battur L., Bedbrook A., Bedolla Barajas M., Beghe B., Bel E., Ben Kheder A., Benson M., Berghea C., Bergmann K. -C., Bernstein D., Bewick M., Bialek S., Bialoszewski A., Bieber T., Billo N., Bilo M. B., Bindslev-Jensen C., Bjermer L., Bochenska Marciniak M., Bond C., Boner A., Bonini M., Bonini S., Bosnic-Anticevich S., Bosse I., Botskariova S., Bouchard J., Boulet L. -P., Bourret R., Bousquet P., Braido F., Briggs A., Brightling C., Brozek J., Buhl R., Bumbacea R., Burguete Cabanas M. T., Bush A., Busse W. W., Buters J., Caballero-Fonseca F., Calderon M. A., Calvo M., Camargos P., Camuzat T., Cano A., Capriles-Hulett A., Caraballo L., Carlsen K. -H., Caro J., Carr W., Carreon-Asuncion F., Carriazo A. M., Casale T., Castor M. A., Castro E., Cecchi L., Cepeda Sarabia A., Chandrasekharan R., Chang Y. -S., Chato-Andeza V., Chatzi L., Chatzidaki C., Chavannes N. H., Chen Y., Cheng L., Chivato T., Chkhartishvili E., Christoff G., Chrystyn H., Chu D. K., Chua A., Chuchalin A., Chung K. F., Ciceran A., Cingi C., Ciprandi G., Cirule I., Coelho A. C., Constantinidis J., Correia De Sousa J., Costa E., Costa D., Costa Dominguez M. D. C., Coste A., Cox L., Cullen J., Custovic A., Cvetkovski B., D'Amato G., Da Silva J., Dahl R., Dahlen S. -E., Daniilidis V., Darjazini Nahhas L., Darsow U., De Blay F., De Guia E., De Los Santos C., De Manuel Keenoy E., De Vries G., Deleanu D., Demoly P., Denburg J., Devillier P., Didier A., Dimou M., Dinh-Xuan A. T., Djukanovic R., Dokic D., Dominguez Silva M. G., Douagui H., Douladiris N., Doulaptsi M., Dray G., Dubakiene R., Durham S., Dykewicz M., Ebo D., Edelbaher N., Eklund P., El-Gamal Y., El-Sayed Z. A., El-Sayed S. S., El-Seify M., Emuzyte R., Enecilla L., Espinoza H., Espinoza Contreras J. G., Farrell J., Fernandez L., Fink Wagner A., Fiocchi A., Fokkens W. J., Fontaine J. -F., Forastiere F., Fuentes Perez J. M., Gaerlan-Resureccion E., Gaga M., Galvez Romero J. L., Gamkrelidze A., Garcia A., Garcia Cobas C. Y., Garcia Cruz M. D. L. L. H., Gayraud J., Gemicioglu B., Genova S., Gereda J., Gerth Van Wijk R., Gomez M., Gonzalez Diaz S., Gotua M., Grigoreas C., Grisle I., Guidacci M., Guldemond N., Gutter Z., Guzman A., Halloum R., Hamelmann E., Hammadi S., Harvey R., Heinrich J., Hejjaoui A., Hellquist-Dahl B., Hernandez Velazquez L., Hew M., Hossny E., Howarth P., Hrubisko M., Huerta Villalobos Y. R., Humbert M., Hyland M., Ibrahim M., Ilyina N., Irani C., Ispayeva Z., Jares E., Jarvis D., Jassem E., Jenko K., Jimeneracruz Uscanga R. D., Johnston S., Joos G., Jost M., Julge K., Jung K. -S., Just J., Kaidashev I., Kalayci O., Kalyoncu F., Kapsali J., Kardas P., Karjalainen J., Kasala C. A., Katotomichelakis M., Kazi B., Keil T., Keith P., Khaitov M., Khaltaev N., Kim Y. -Y., Kleine-Tebbe J., Koffi N'Goran B., Kompoti E., Kopac P., Koppelman G., Koren Jeverica A., Kosnik M., Kostov K. V., Kowalski M. L., Kralimarkova T., Kramer Vrscaj K., Kraxner H., Kreft S., Kritikos V., Kudlay D., Kull I., Kupczyk M., Kvedariene V., Kyriakakou M., Lalek N., Lane S., Latiff A., Lau S., Lavrut J., Le L., Lessa M., Levin M., Li J., Lieberman P., Liotta G., Lipworth B., Liu X., Lobo R., Lodrup Carlsen K. C., Lombardi C., Louis R., Loukidis S., Lourenco O., Luna Pech J. A., Madjar B., Magnan A., Mahboub B., Mair A., Mais Y., Maitland Van Der Zee A. -H., Makela M., Makris M., Malling H. -J., Mandajieva M., Manning P., Manousakis M., Maragoudakis P., Marshall G., Martinsmartins P., Masjedi M. R., Maspero J. F., Matta Campos J. J., Maurer M., Mavale-Manuel S., Meco C., Melen E., Melo-Gomes E., Meltzer E. O., Menditto E., Menzies-Gow A., Merk H., Michel J. -P., Miculinic N., Midao L., Mihaltan F., Mikael K., Mikos N., Milenkovic B., Mitsias D., Moalla B., Moda G., Mogica Martinez M. D., Mohammad Y., Moin M., Molimard M., Momas I., Monaco A., Montefort S., Mora D., Morais-Almeida M., Mosges R., Mostafa B. E., Munter L., Muraro A., Murray R., Mustakov T., Naclerio R., Nadif R., Nakonechna A., Namazova-Baranova L., Navarro-Locsin G., Neffen H., Nekam K., Neou A., Nicod L., Niederberger-Leppin V., Niedoszytko M., Nieto A., Novellino E., Nunes E., Nyembue D., O'Hehir R., Odjakova C., Ohta K., Okamoto Y., Okubo K., Oliver B., Onorato G. L., Orru M. P., Ouedraogo S., Ouoba K., Paggiaro P. L., Pagkalos A., Palaniappan S. P., Pali-Scholl I., Palkonen S., Palmer S., Panaitescu Bunu C., Panzner P., Papanikolaou V., Papi A., Paralchev B., Paraskevopoulos G., Park H. S., Passalacqua G., Patella V., Pavord I., Pawankar R., Pedersen S., Peleve S., Pereira A., Perez T., Pham-Thi N., Pigearias B., Pin I., Piskou K., Pitsios C., Pitsios K., Plavec D., Poethig D., Pohl W., Poplas Susic A., Popov T. A., Portejoie F., Potter P., Poulsen L., Prados-Torres A., Prarros F., Price D., Prokopakis E., Puy R., Rabe K., Raciborski F., Ramos J., Recto M. T., Reda S. M., Regateiro F., Reider N., Reitsma S., Repka-Ramirez S., Rimmer J., Rivero Yeverino D., Rizzo J. A., Robalo-Cordeiro C., Roberts G., Roche N., Rodriguez Gonzalez M., Rodriguez Zagal E., Rolland C., Roller-Wirnsberger R., Roman Rodriguez M., Romano A., Rombaux P., Romualdez J., Rosado-Pinto J., Rosario N., Rosenwasser L., Rottem M., Rouadi P., Rovina N., Rozman Sinur I., Ruiz M., Ruiz Segura L. T., Ryan D., Sagara H., Sakai D., Sakurai D., Saleh W., Salimaki J., Salina H., Samitas K., Sanchez Coronel M. G., Sanchez-Borges M., Sanchez-Lopez J., Sarafoleanu C., Sarquis Serpa F., Sastre-Dominguez J., Scadding G., Scheire S., Schmid-Grendelmeier P., Schuhl J. F., Schunemann H., Schvalbova M., Scichilone N., Sepulveda C., Serrano E., Sheikh A., Shields M., Shishkov V., Siafakas N., Simeonov A., Simons E. F., Sisul J. C., Sitkauskiene B., Skrindo I., Soklic Kosak T., Sole D., Sooronbaev T., Soto-Martinez M., Sova M., Spertini F., Spranger O., Stamataki S., Stefanaki L., Stellato C., Stelmach R., Sterk P., Strandberg T., Stute P., Subramaniam A., Suppli Ulrik C., Sutherland M., Sylvestre S., Syrigou A., Taborda Barata L., Takovska N., Tan R., Tan F., Tan V., Tang I. P., Taniguchi M., Tannert L., Tattersall J., Teixeira M. D. C., Thijs C., Thomas M., To T., Todo-Bom A. M., Togias A., Tomazic P. -V., Toppila-Salmi S., Toskala E., Triggiani M., Triller N., Triller K., Tsiligianni I., Ulmeanu R., Urbancic J., Urrutia Pereira M., Vachova M., Valdes F., Valenta R., Valentin Rostan M., Valero A., Vallianatou M., Valovirta E., Van Eerd M., Van Ganse E., Van Hage M., Vandenplas O., Vasankari T., Vassileva D., Ventura M. T., Vera-Munoz C., Vicheva D., Vichyanond P., Vidgren P., Viegi G., Vogelmeier C., Von Hertzen L., Vontetsianos T., Vourdas D., Wagenmann M., Walker S., Wallace D., Wang D. Y., Waserman S., Wickman M., Williams S., Williams D., Wilson N., Woo K., Wright J., Wroczynski P., Xepapadaki P., Yakovliev P., Yamaguchi M., Yan K., Yap Y. Y., Yawn B., Yiallouros P., Yoshihara S., Young I., Yusuf O. B., Zaidi A., Zaitoun F., Zar H., Zernotti M., Zhang L., Zhong N., Zidarn M., Zubrinich C., UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Bousquet J., Anto J.M., Iaccarino G., Czarlewski W., Haahtela T., Anto A., Akdis C.A., Blain H., Canonica G.W., Cardona V., Cruz A.A., Illario M., Ivancevich J.C., Jutel M., Klimek L., Kuna P., Laune D., Larenas-linnemann D., Mullol J., Papadopoulos N.G., Pfaar O., Samolinski B., Valiulis A., Yorgancioglu A., Zuberbier T., Abdul Latiff A.H., Abdullah B., Aberer W., Abusada N., Adcock I., Afani A., Agache I., Aggelidis X., Agustin J., Akdis C., Akdis M., Al-Ahmad M., Bassam A.A.-Z., Aldrey-Palacios O., Cuesta E.A., Alzaabi A., Amad S., Ambrocio G., Annesi-Maesano I., Ansotegui I., Anto J., Arshad H., Artesani M.C., Asayag E., Avolio F., Azhari K., Baiardini I., Bajrovic N., Bakakos P., Mongono S.B., Balotro-Torres C., Barba S., Barbara C., Barbosa E., Barreto B., Bartra J., Bateman E.D., Battur L., Bedbrook A., Barajas M.B., Beghe B., Bel E., Kheder A.B., Benson M., Berghea C., Bergmann K.-C., Bernstein D., Bewick M., Bialek S., Bialoszewski A., Bieber T., Billo N., Bilo M.B., Bindslev-Jensen C., Bjermer L., Marciniak M.B., Bond C., Boner A., Bonini M., Bonini S., Bosnic-Anticevich S., Bosse I., Botskariova S., Bouchard J., Boulet L.-P., Bourret R., Bousquet P., Braido F., Briggs A., Brightling C., Brozek J., Buhl R., Bumbacea R., Cabanas M.T.B., Bush A., Busse W.W., Buters J., Caballero-Fonseca F., Calderon M.A., Calvo M., Camargos P., Camuzat T., Cano A., Capriles-Hulett A., Caraballo L., Carlsen K.-H., Caro J., Carr W., Carreon-Asun-cion F., Carriazo A.M., Casale T., Castor M.A., Castro E., Cecchi L., Sarabia A.C., Chandrasekharan R., Chang Y.-S., Chato-Andeza V., Chatzi L., Chatzidaki C., Chavannes N.H., Chen Y., Cheng L., Chivato T., Chkhartishvili E., Christoff G., Chrystyn H., Chu D.K., Chua A., Chuchalin A., Chung K.F., Ciceran A., Cingi C., Ciprandi G., Cirule I., Coelho A.C., Constantinidis J., de Sousa J.C., Costa E., Costa D., Dominguez M.C.C., Coste A., Cox L., Cullen J., Custovic A., Cvetkovski B., D'amato G., Silva J.D., Dahl R., Dahlen S.-E., Daniilidis V., Nahhas L.D., Darsow U., Blay F., Guia E.D., Santos C., Keenoy E.D.M., Vries G.D., Deleanu D., Demoly P., Denburg J., Devillier P., Didier A., Dimou M., Dinh-Xuan A.T., Djukanovic R., Dokic D., Dominguez Silva M.G., Douagui H., Douladiris N., Doulaptsi M., Dray G., Dubakiene R., Durham S., Dykewicz M., Ebo D., Edelbaher N., Eklund P., El-Gamal Y., El-Sayed Z.A., El-Sayed S.S., El-Seify M., Emuzyte R., Enecilla L., Espinoza H., Guillermo J., Contreras E., Farrell J., Fernandez L., Wagner A.F., Fiocchi A., Fokkens W.J., Fontaine J.-F., Forastiere F., Perez J.M.F., Gaerlan-resureccion E., Gaga M., Romero J.L.G., Gamkrelidze A., Garcia A., Cobas C.Y.G., Garcia Cruz M.L.L.H., Gayraud J., Gemicioglu B., Genova S., Gereda J., Wijk R.G., Gomez M., Diaz S.G., Gotua M., Grigoreas C., Grisle I., Guidacci M., Guldemond N., Gutter Z., Guzman A., Halloum R., Hamelmann E., Hammadi S., Harvey R., Heinrich J., Hejjaoui A., Hellquist-Dahl B., Velazquez L.H., Hew M., Hossny E., Howarth P., Hrubisko M., Villalobos Y.R.H., Humbert M., Hyland M., Ibrahim M., Ilyina N., Irani C., Ispayeva Z., Jares E., Jarvis D., Jassem E., Jenko K., Uscanga R.D.J., Johnston S., Joos G., Jost M., Julge K., Jung K.-S., Just J., Kaidashev I., Kalayci O., Kalyoncu F., Kapsali J., Kardas P., Karjalainen J., Kasala C.A., Katotomichelakis M., Kazi B., Keil T., Keith P., Khaitov M., Khaltaev N., Kim Y.-Y., Kleine-Tebbe J., Koffi N'Goran B., Kompoti E., Kopac P., Koppelman G., Jeverica A.K., Kosnik M., Kostov K.V., Kowalski M.L., Kralimarkova T., Vrscaj K.K., Kraxner H., Kreft S., Kritikos V., Kudlay D., Kull I., Kupczyk M., Kvedariene V., Kyriakakou M., Lalek N., Lane S., Larenas-Linnemann D., Latiff A., Lau S., Lavrut J., Le L., Lessa M., Levin M., Li J., Lieberman P., Liotta G., Lipworth B., Liu X., Lobo R., Lodrup Carlsen K.C., Lombardi C., Louis R., Loukidis S., Lourenco O., Luna Pech J.A., Madjar B., Magnan A., Mahboub B., Mair A., Mais Y., van der Zee A.-H.M., Makela M., Makris M., Malling H.-J., Mandajieva M., Manning P., Manousakis M., Maragoudakis P., Marshall G., Martins P., Reza Masjedi M., Maspero J.F., Campos J.J.M., Maurer M., Mavale-Manuel S., Meco C., Melen E., Melo-Gomes E., Meltzer E.O., Menditto E., Menzies-Gow A., Merk H., Michel J.-P., Miculinic N., Midao L., Mihaltan F., Mikael K., Mikos N., Milenkovic B., Mitsias D., Moalla B., Moda G., Martinez M.D.M., Mohammad Y., Moin M., Molimard M., Momas I., Monaco A., Montefort S., Mora D., Morais-Almeida M., Mosges R., Mostafa B.E., Munter L., Muraro A., Murray R., Mustakov T., Naclerio R., Nadif R., Nakonechna A., Namazova-Baranova L., Navarro-Locsin G., Neffen H., Nekam K., Neou A., Nicod L., Niederberger-Leppin V., Niedoszytko M., Nieto A., Novellino E., Nunes E., Nyembue D., O'hehir R., Odjakova C., Ohta K., Okamoto Y., Okubo K., Oliver B., Onorato G.L., Orru M.P., Ouedraogo S., Ouoba K., Paggiaro P.L., Pagkalos A., Palaniappan S.P., Pali-Scholl I., Palkonen S., Palmer S., Bunu C.P., Panzner P., Papanikolaou V., Papi A., Paralchev B., Paraskevopoulos G., Park H.S., Passalacqua G., Patella V., Pavord I., Pawankar R., Pedersen S., Peleve S., Pereira A., Perez T., Pham-Thi N., Pigearias B., Pin I., Piskou K., Pitsios C., Pitsios K., Plavec D., Poethig D., Pohl W., Susic A.P., Popov T.A., Portejoie F., Potter P., Poulsen L., Prados-Torres A., Prarros F., Price D., Prokopakis E., Puy R., Rabe K., Raciborski F., Ramos J., Recto M.T., Reda S.M., Regateiro F., Reider N., Reitsma S., Repka-Ramirez S., Rimmer J., Yeverino D.R., Rizzo J.A., Robalo-Cordeiro C., Roberts G., Roche N., Gonzalez M.R., Zagal E.R., Rolland C., Roller-Wirns-berger R., Rodriguez M.R., Romano A., Rombaux P., Romualdez J., Rosado-Pinto J., Rosario N., Rosenwasser L., Rottem M., Rouadi P., Rovina N., Sinur I.R., Ruiz M., Segura L.T.R., Ryan D., Sagara H., Sakai D., Sakurai D., Saleh W., Salimaki J., Salina H., Samitas K.-N., Coronel M.G.S., Sanchez-Borges M., Sanchez-Lopez J., Sarafoleanu C., Serpa F.S., Sastre-Dominguez J., Scadding G., Scheire S., Schmid-Grendelmeier P., Schuhl J.F., Schunemann H., Schvalbova M., Scichilone N., Sepulveda C., Serrano E., Sheikh A., Shields M., Shishkov V., Siafakas N., Simeonov A., Simons E.F., Sisul J.C., Sitkauskiene B., Skrindo I., Kosak T.S., Sole D., Sooronbaev T., Soto-Martinez M., Sova M., Spertini F., Spranger O., Stamataki S., Stefanaki L., Stellato C., Stelmach R., Sterk P., Strandberg T., Stute P., Subramaniam A., Suppli Ulrik C., Sutherland M., Sylvestre S., Syrigou A., Barata L.T., Takovska N., Tan R., Tan F., Tan V., Tang I.P., Taniguchi M., Tannert L., Tattersall J., Teixeira M.D.C., Thijs C., Thomas M., To T., Todo-Bom A.M., Togias A., Tomazic P.-V., Toppila-Salmi S., Toskala E., Triggiani M., Triller N., Triller K., Tsiligianni I., Ulmeanu R., Urbancic J., Pereira M.U., Vachova M., Valdes F., Valenta R., Rostan M.V., Valero A., Vallianatou M., Valovirta E., Eerd M.V., Ganse E.V., Hage M., Vandenplas O., Vasankari T., Vassileva D., Ventura T., Vera-Munoz C., Vicheva D., Vichyanond P., Vidgren P., Viegi G., Vogelmeier C., Hertzen L.V., Vontetsianos T., Vourdas D., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Wickman M., Williams S., Williams D., Wilson N., Woo K., Wright J., Wroczynski P., Xepapadaki P., Yakovliev P., Yamaguchi M., Yan K., Yap Y.Y., Yawn B., Yiallouros P., Yoshihara S., Young I., Yusuf O.B., Zaidi A., Zaitoun F., Zar H., Zernotti M., Zhang L., Zhong N., Zidarn M., Zubrinich C., Dubakienė, Rūta, Ėmužytė, Regina, Kvedarienė, Violeta, Bousquet, J., Anto, J. M., Iaccarino, G., Czarlewski, W., Haahtela, T., Anto, A., Akdis, C. A., Blain, H., Canonica, G. W., Cardona, V., Cruz, A. A., Illario, M., Ivancevich, J. C., Jutel, M., Klimek, L., Kuna, P., Laune, D., Larenas-Linnemann, D., Mullol, J., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Abdul Latiff, A. H., Abdullah, B., Aberer, W., Abusada, N., Adcock, I., Afani, A., Agache, I., Aggelidis, X., Agustin, J., Akdis, C., Akdis, M., Al-Ahmad, M., Al-Zahab Bassam, A., Aldrey-Palacios, O., Alvarez Cuesta, E., Alzaabi, A., Amad, S., Ambrocio, G., Annesi-Maesano, I., Ansotegui, I., Anto, J., Arshad, H., Artesani, M. C., Asayag, E., Avolio, F., Azhari, K., Baiardini, I., Bajrovic, N., Bakakos, P., Bakeyala Mongono, S., Balotro-Torres, C., Barba, S., Barbara, C., Barbosa, E., Barreto, B., Bartra, J., Bateman, E. D., Battur, L., Bedbrook, A., Bedolla Barajas, M., Beghe, B., Bel, E., Ben Kheder, A., Benson, M., Berghea, C., Bergmann, K. -C., Bernstein, D., Bewick, M., Bialek, S., Bialoszewski, A., Bieber, T., Billo, N., Bilo, M. B., Bindslev-Jensen, C., Bjermer, L., Bochenska Marciniak, M., Bond, C., Boner, A., Bonini, M., Bonini, S., Bosnic-Anticevich, S., Bosse, I., Botskariova, S., Bouchard, J., Boulet, L. -P., Bourret, R., Bousquet, P., Braido, F., Briggs, A., Brightling, C., Brozek, J., Buhl, R., Bumbacea, R., Burguete Cabanas, M. T., Bush, A., Busse, W. W., Buters, J., Caballero-Fonseca, F., Calderon, M. A., Calvo, M., Camargos, P., Camuzat, T., Cano, A., Capriles-Hulett, A., Caraballo, L., Carlsen, K. -H., Caro, J., Carr, W., Carreon-Asuncion, F., Carriazo, A. M., Casale, T., Castor, M. A., Castro, E., Cecchi, L., Cepeda Sarabia, A., Chandrasekharan, R., Chang, Y. -S., Chato-Andeza, V., Chatzi, L., Chatzidaki, C., Chavannes, N. H., Chen, Y., Cheng, L., Chivato, T., Chkhartishvili, E., Christoff, G., Chrystyn, H., Chu, D. K., Chua, A., Chuchalin, A., Chung, K. F., Ciceran, A., Cingi, C., Ciprandi, G., Cirule, I., Coelho, A. C., Constantinidis, J., Correia De Sousa, J., Costa, E., Costa, D., Costa Dominguez, M. D. C., Coste, A., Cox, L., Cullen, J., Custovic, A., Cvetkovski, B., D'Amato, G., Da Silva, J., Dahl, R., Dahlen, S. -E., Daniilidis, V., Darjazini Nahhas, L., Darsow, U., De Blay, F., De Guia, E., De Los Santos, C., De Manuel Keenoy, E., De Vries, G., Deleanu, D., Demoly, P., Denburg, J., Devillier, P., Didier, A., Dimou, M., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Dominguez Silva, M. G., Douagui, H., Douladiris, N., Doulaptsi, M., Dray, G., Dubakiene, R., Durham, S., Dykewicz, M., Ebo, D., Edelbaher, N., Eklund, P., El-Gamal, Y., El-Sayed, Z. A., El-Sayed, S. S., El-Seify, M., Emuzyte, R., Enecilla, L., Espinoza, H., Espinoza Contreras, J. G., Farrell, J., Fernandez, L., Fink Wagner, A., Fiocchi, A., Fokkens, W. J., Fontaine, J. -F., Forastiere, F., Fuentes Perez, J. M., Gaerlan-Resureccion, E., Gaga, M., Galvez Romero, J. L., Gamkrelidze, A., Garcia, A., Garcia Cobas, C. Y., Garcia Cruz, M. D. L. L. H., Gayraud, J., Gemicioglu, B., Genova, S., Gereda, J., Gerth Van Wijk, R., Gomez, M., Gonzalez Diaz, S., Gotua, M., Grigoreas, C., Grisle, I., Guidacci, M., Guldemond, N., Gutter, Z., Guzman, A., Halloum, R., Hamelmann, E., Hammadi, S., Harvey, R., Heinrich, J., Hejjaoui, A., Hellquist-Dahl, B., Hernandez Velazquez, L., Hew, M., Hossny, E., Howarth, P., Hrubisko, M., Huerta Villalobos, Y. R., Humbert, M., Hyland, M., Ibrahim, M., Ilyina, N., Irani, C., Ispayeva, Z., Jares, E., Jarvis, D., Jassem, E., Jenko, K., Jimeneracruz Uscanga, R. D., Johnston, S., Joos, G., Jost, M., Julge, K., Jung, K. -S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, F., Kapsali, J., Kardas, P., Karjalainen, J., Kasala, C. A., Katotomichelakis, M., Kazi, B., Keil, T., Keith, P., Khaitov, M., Khaltaev, N., Kim, Y. -Y., Kleine-Tebbe, J., Koffi N'Goran, B., Kompoti, E., Kopac, P., Koppelman, G., Koren Jeverica, A., Kosnik, M., Kostov, K. V., Kowalski, M. L., Kralimarkova, T., Kramer Vrscaj, K., Kraxner, H., Kreft, S., Kritikos, V., Kudlay, D., Kull, I., Kupczyk, M., Kvedariene, V., Kyriakakou, M., Lalek, N., Lane, S., Latiff, A., Lau, S., Lavrut, J., Le, L., Lessa, M., Levin, M., Li, J., Lieberman, P., Liotta, G., Lipworth, B., Liu, X., Lobo, R., Lodrup Carlsen, K. C., Lombardi, C., Louis, R., Loukidis, S., Lourenco, O., Luna Pech, J. A., Madjar, B., Magnan, A., Mahboub, B., Mair, A., Mais, Y., Maitland Van Der Zee, A. -H., Makela, M., Makris, M., Malling, H. -J., Mandajieva, M., Manning, P., Manousakis, M., Maragoudakis, P., Marshall, G., Martinsmartins, P., Masjedi, M. R., Maspero, J. F., Matta Campos, J. J., Maurer, M., Mavale-Manuel, S., Meco, C., Melen, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Menzies-Gow, A., Merk, H., Michel, J. -P., Miculinic, N., Midao, L., Mihaltan, F., Mikael, K., Mikos, N., Milenkovic, B., Mitsias, D., Moalla, B., Moda, G., Mogica Martinez, M. D., Mohammad, Y., Moin, M., Molimard, M., Momas, I., Monaco, A., Montefort, S., Mora, D., Morais-Almeida, M., Mosges, R., Mostafa, B. E., Munter, L., Muraro, A., Murray, R., Mustakov, T., Naclerio, R., Nadif, R., Nakonechna, A., Namazova-Baranova, L., Navarro-Locsin, G., Neffen, H., Nekam, K., Neou, A., Nicod, L., Niederberger-Leppin, V., Niedoszytko, M., Nieto, A., Novellino, E., Nunes, E., Nyembue, D., O'Hehir, R., Odjakova, C., Ohta, K., Okamoto, Y., Okubo, K., Oliver, B., Onorato, G. L., Orru, M. P., Ouedraogo, S., Ouoba, K., Paggiaro, P. L., Pagkalos, A., Palaniappan, S. P., Pali-Scholl, I., Palkonen, S., Palmer, S., Panaitescu Bunu, C., Panzner, P., Papanikolaou, V., Papi, A., Paralchev, B., Paraskevopoulos, G., Park, H. S., Passalacqua, G., Patella, V., Pavord, I., Pawankar, R., Pedersen, S., Peleve, S., Pereira, A., Perez, T., Pham-Thi, N., Pigearias, B., Pin, I., Piskou, K., Pitsios, C., Pitsios, K., Plavec, D., Poethig, D., Pohl, W., Poplas Susic, A., Popov, T. A., Portejoie, F., Potter, P., Poulsen, L., Prados-Torres, A., Prarros, F., Price, D., Prokopakis, E., Puy, R., Rabe, K., Raciborski, F., Ramos, J., Recto, M. T., Reda, S. M., Regateiro, F., Reider, N., Reitsma, S., Repka-Ramirez, S., Rimmer, J., Rivero Yeverino, D., Rizzo, J. A., Robalo-Cordeiro, C., Roberts, G., Roche, N., Rodriguez Gonzalez, M., Rodriguez Zagal, E., Rolland, C., Roller-Wirnsberger, R., Roman Rodriguez, M., Romano, A., Rombaux, P., Romualdez, J., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Rouadi, P., Rovina, N., Rozman Sinur, I., Ruiz, M., Ruiz Segura, L. T., Ryan, D., Sagara, H., Sakai, D., Sakurai, D., Saleh, W., Salimaki, J., Salina, H., Samitas, K., Sanchez Coronel, M. G., Sanchez-Borges, M., Sanchez-Lopez, J., Sarafoleanu, C., Sarquis Serpa, F., Sastre-Dominguez, J., Scadding, G., Scheire, S., Schmid-Grendelmeier, P., Schuhl, J. F., Schunemann, H., Schvalbova, M., Scichilone, N., Sepulveda, C., Serrano, E., Sheikh, A., Shields, M., Shishkov, V., Siafakas, N., Simeonov, A., Simons, E. F., Sisul, J. C., Sitkauskiene, B., Skrindo, I., Soklic Kosak, T., Sole, D., Sooronbaev, T., Soto-Martinez, M., Sova, M., Spertini, F., Spranger, O., Stamataki, S., Stefanaki, L., Stellato, C., Stelmach, R., Sterk, P., Strandberg, T., Stute, P., Subramaniam, A., Suppli Ulrik, C., Sutherland, M., Sylvestre, S., Syrigou, A., Taborda Barata, L., Takovska, N., Tan, R., Tan, F., Tan, V., Tang, I. P., Taniguchi, M., Tannert, L., Tattersall, J., Teixeira, M. D. C., Thijs, C., Thomas, M., To, T., Todo-Bom, A. M., Togias, A., Tomazic, P. -V., Toppila-Salmi, S., Toskala, E., Triggiani, M., Triller, N., Triller, K., Tsiligianni, I., Ulmeanu, R., Urbancic, J., Urrutia Pereira, M., Vachova, M., Valdes, F., Valenta, R., Valentin Rostan, M., Valero, A., Vallianatou, M., Valovirta, E., Van Eerd, M., Van Ganse, E., Van Hage, M., Vandenplas, O., Vasankari, T., Vassileva, D., Ventura, M. T., Vera-Munoz, C., Vicheva, D., Vichyanond, P., Vidgren, P., Viegi, G., Vogelmeier, C., Von Hertzen, L., Vontetsianos, T., Vourdas, D., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Wickman, M., Williams, S., Williams, D., Wilson, N., Woo, K., Wright, J., Wroczynski, P., Xepapadaki, P., Yakovliev, P., Yamaguchi, M., Yan, K., Yap, Y. Y., Yawn, B., Yiallouros, P., Yoshihara, S., Young, I., Yusuf, O. B., Zaidi, A., Zaitoun, F., Zar, H., Zernotti, M., Zhang, L., Zhong, N., Zidarn, M., Zubrinich, C., University of Zurich, Bousquet, Jean, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, IMIM-Hospital del Mar, Generalitat de Catalunya, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), 'Federico II' University of Naples Medical School, Medical Consulting Czarlewski, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Euromov (EuroMov), Université de Montpellier (UM), IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy., Vall d'Hebron University Hospital [Barcelona], ProAR – Nucleo de Excelencia em Asma, Universidade Federal da Bahia (UFBA), Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Division for Health Innovation, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Wrocław Medical University, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Barlicki University Hospital, KYomed INNOV [Montpellier], Hospital Medica Sur [Mexico City, Mexico], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, Philipps Universität Marburg = Philipps University of Marburg, Medical University of Warsaw - Poland, Vilnius University [Vilnius], Manisa Celal Bayar University, and Salvy-Córdoba, Nathalie
- Subjects
BLOOD-PRESSURE ,Review ,Angiotensin-converting enzyme ,Antioxidant ,Coronavirus ,Diet ,Food ,law.invention ,Dietary interventions ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,10183 Swiss Institute of Allergy and Asthma Research ,law ,Medicine and Health Sciences ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,education.field_of_study ,Mortality rate ,3. Good health ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,2723 Immunology and Allergy ,Angiotensin-converting enzyme, Antioxidant, Coronavirus, Diet, Food ,Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Coronaviru ,Immunology ,Population ,610 Medicine & health ,COVID-19 ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,03 medical and health sciences ,Environmental health ,population ,angiotensin-converting enzyme ,Quarantine ,education ,2403 Immunology ,ANTIHYPERTENSIVE PEPTIDES ,business.industry ,RC581-607 ,GENE ,POLYMORPHISM ,[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition ,030228 respiratory system ,2740 Pulmonary and Respiratory Medicine ,Immunologic diseases. Allergy ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,Regional differences ,Coronavirus Infections - Abstract
Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.
- Published
- 2020
4. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
- Author
-
Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), Foa R., Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), and Foa R.
- Abstract
Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occu
- Published
- 2022
5. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
- Author
-
Karakatsanis, S.J. Bouzani, M. Symeonidis, A. Angelopoulou, M.K. Papageorgiou, S.G. Michail, M. Gainaru, G. Kourti, G. sachanas, S. Kalpadakis, C. Katodritou, E. Leonidopoulou, T. Kotsianidis, I. Hatzimichael, E. Kotsopoulou, M. Dimou, M. Variamis, E. Boutsis, D. Kanellias, N. Dimopoulou, M.N. Michali, E. Karianakis, G. Tsirkinidis, P. Vadikolia, C. Poziopoulos, C. Pigaditou, A. Vrakidou, E. Economopoulos, T. Kyriazopoulou, L. Siakantaris, M.P. Kyrtsonis, M.-C. Anargyrou, K. Papaioannou, M. Hatjiharissi, E. Vervessou, E. Tsirogianni, M. Palassopoulou, M. Stefanoudaki, E. Zikos, P. Tsirigotis, P. Tsourouflis, G. Assimakopoulou, T. Verrou, E. Papadaki, H. Lampropoulou, P. Dimopoulos, M.-A. Pappa, V. Konstantopoulos, K. Karmiris, T. Roussou, P. Panayiotidis, P. Pangalis, G.A. Vassilakopoulos, T.P.
- Subjects
immune system diseases ,hemic and lymphatic diseases - Abstract
Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both RCHOP- 21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP- 14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results. © 2022 International Institute of Anticancer Research. All rights reserved.
- Published
- 2022
6. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
- Author
-
Vassilakopoulos, T.P. Papageorgiou, S.G. Angelopoulou, M.K. Chatziioannou, S. Prassopoulos, V. Karakatsanis, S. Arapaki, M. Mellios, Z. Sachanas, S. Kalpadakis, C. Katodritou, E. Leonidopoulou, T. Kotsianidis, I. Hatzimichael, E. Kotsopoulou, M. Dimou, M. Variamis, E. Boutsis, D. Terpos, E. Michali, E. Karianakis, G. Tsirkinidis, P. Vadikolia, C. Poziopoulos, C. Pigaditou, A. Vrakidou, E. Siakantaris, M.P. Kyrtsonis, M.-C. Symeonidis, A. Anargyrou, K. Papaioannou, M. Chatziharissi, E. Vervessou, E. Tsirogianni, M. Palassopoulou, M. Gainaru, G. Mainta, C. Tsirigotis, P. Assimakopoulou, T. Konstantinidou, P. Papadaki, H. Dimopoulos, M.-A. Pappa, V. Karmiris, T. Roussou, P. Datseris, I. Panayiotidis, P. Konstantopoulos, K. Pangalis, G.A. Rondogianni, P.
- Abstract
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET/CT (D5PSS-1/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0/49 vs. 4/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET/CT with D5PSS < 5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
- Published
- 2021
7. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
- Author
-
Pleyer, L. Leisch, M. Kourakli, A. Padron, E. Maciejewski, J.P. Xicoy Cirici, B. Kaivers, J. Ungerstedt, J. Heibl, S. Patiou, P. Hunter, A.M. Mora, E. Geissler, K. Dimou, M. Jimenez Lorenzo, M.-J. Melchardt, T. Egle, A. Viniou, A.-N. Patel, B.J. Arnan, M. Valent, P. Roubakis, C. Bernal del Castillo, T. Galanopoulos, A. Calabuig Muñoz, M. Bonadies, N. Medina de Almeida, A. Cermak, J. Jerez, A. Montoro, M.J. Cortés, A. Avendaño Pita, A. Lopez Andrade, B. Hellstroem-Lindberg, E. Germing, U. Sekeres, M.A. List, A.F. Symeonidis, A. Sanz, G.F. Larcher-Senn, J. Greil, R.
- Subjects
hemic and lymphatic diseases - Abstract
Background: Approval of hypomethylating agents in patients with chronic myelomonocytic leukaemia is based on trials done in patients with myelodysplastic syndromes. We aimed to investigate whether hypomethylating agents provide a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments. Methods: For this retrospective cohort study, data were retrieved between Nov 30, 2017, and Jan 5, 2019, from 38 centres in the USA and Europe. We included non-selected, consecutive patients diagnosed with chronic myelomonocytic leukaemia, who received chronic myelomonocytic leukaemia-directed therapy. Patients with acute myeloid leukaemia according to 2016 WHO criteria at initial diagnosis (ie, ≥20% blasts in the bone marrow or peripheral blood) or with unavailability of treatment data were excluded. Outcomes assessed included overall survival, time to next treatment, and time to transformation to acute myeloid leukaemia. Analyses were adjusted by age, sex, platelet count, and Chronic myelomonocytic leukaemia-Specific Prognostic Scoring System (CPSS). Patients were grouped by first received treatment with either hydroxyurea, hypomethylating agents, or intensive chemotherapy, and stratified by risk according to blast count, French-American-British subtype, CPSS, WHO 2016 subtype, and the eligibility criteria of the DACOTA trial (NCT02214407). Findings: 949 patients diagnosed with chronic myelomonocytic leukaemia between April 13, 1981, and Oct 26, 2018, were included. Median follow-up was 23·4 months (IQR 11·5–42·3) from diagnosis and 16·2 months (6·6–31·6) from start of first-line treatment. 412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy. Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15·6 months (95% CI 13·1–17·3) versus 20·7 months (17·9–23·4); hazard ratio (HR) 1·39 (1·17–1·65; p=0·0002) and 14·0 months (9·8–17·2) versus 20·7 months (17·9–23·4; HR 1·55 [1·16–2·05]; p=0·0027) for those treated with intensive chemotherapy versus hypomethylating agents. In patients with myeloproliferative chronic myelomonocytic leukaemia (myeloproliferative CMML), median overall survival was 12·6 months (10·7–15·0) versus 17·6 months (14·8–21·5; HR 1·38 [1·12–1·70]; p=0·0027) for patients treated with hydroxyurea versus hypomethylating agents, and 12·3 months (8·4–16·6) versus 17·6 months (14·8–21·5; HR 1·44 [1·02–2·03]; p=0·040) for intensive chemotherapy versus hypomethylating agents. Hypomethylating agents did not confer an overall survival advantage for patients classified as having lower-risk disease (ie, myelodysplastic chronic myelomonocytic leukaemia with
- Published
- 2021
8. Pembrolizumab-induced remission after failure of axicabtagene ciloleucel: Case report and literature review
- Author
-
Dimou, M. Bitsani, A. Bethge, W. Panayiotidis, P. Vassilakopoulos, T.P.
- Abstract
Background: Failure after CD19-directed chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell B non-Hodgkin lymphoma, especially when it happens early, is an emerging clinical problem. There are no specific recommendations and therefore treatment of these patients remains empiricaI. Immune checkpoint inhibitors are becoming a therapeutic option for these patients. Case Report: We present a case of a primary mediastinal large B-cell lymphoma who experienced relapse 3.5 months after axicabtageneciloleucel therapy and received pembrolizumab. After four cycles of pembrolizumab, complete metabolic response was confirmed. Treatment was discontinued after the sixth cycle due to immune checkpoint inhibitor-related pneumonitis. The disease remains in remission 8 months after the last pembrolizumab dose. We propose mechanisms of action and optimal duration of pembrolizumab treatment in this setting. Finally, we review the existing literature on the sequential administration of CD19-directed CAR T-cell therapy and immune checkpoint inhibitors. Conclusion: Immune checkpoint inhibitors are a promising treatment option for patients after failure of CD19-directed CAR-T cell therapy. © 2021 International Institute of Anticancer Research. All rights reserved.
- Published
- 2021
9. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database
- Author
-
Vassilakopoulos, T.P. Piperidou, A. Hadjiharissi, E. Panteliadou, A.-K. Panitsas, F. Vassilopoulos, I. Variamis, E. Boutsis, D. Michail, M. Papageorgiou, S. Tsourouflis, G. Dimou, M. Karakatsanis, S. Kalpadakis, C. Stavroyianni, N. Katodritou, E. Kotsopoulou, M. Kotsianidis, I. Verigou, E. Hatzimichael, E. Leonidopoulou, T. Xanthopoulos, V. Panayiotidis, P. Konstantopoulos, K. Dimopoulos, M.-A. Karmiris, T. Batsis, I. Papaioannou, M. Pangalis, G.A. Angelopoulou, M.K.
- Published
- 2021
10. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas
- Author
-
Dimou, M. Papageorgiou, S.G. Stavroyianni, N. Katodritou, E. Tsirogianni, M. Kalpadakis, C. Banti, A. Arapaki, M. Iliakis, T. Bouzani, M. Verrou, E. Spanoudakis, E. Giannouli, S. Marinakis, T. Mandala, E. Mparmparousi, D. Sachanas, S. Dalekou-Tsolakou, M. Hatzimichael, E. Vadikolia, C. Violaki, V. Poziopoulos, C. Tsirkinidis, P. Chatzileontiadou, S. Vervessou, E. Ximeri, M. Sioni, A. Konstantinidou, P. Kyrtsonis, M.-C. Siakantaris, M.P. Angelopoulou, M.K. Pappa, V. Konstantopoulos, K. Panayiotidis, P. Vassilakopoulos, T.P.
- Abstract
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression–free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 months respectively, while 55% of patients experienced a grade ≥3 adverse event, mainly hematologic. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. © 2021 John Wiley & Sons Ltd.
- Published
- 2021
11. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
- Author
-
Liapis, K. Papadopoulos, V. Vrachiolias, G. Galanopoulos, A.G. Papoutselis, M. Papageorgiou, S.G. Diamantopoulos, P.T. Pappa, V. Viniou, N.-A. Kourakli, A. Τsokanas, D. Vassilakopoulos, T.P. Hatzimichael, E. Bouronikou, E. Ximeri, M. Pontikoglou, C. Megalakaki, A. Zikos, P. Panayiotidis, P. Dimou, M. Karakatsanis, S. Papaioannou, M. Vardi, A. Kontopidou, F. Harchalakis, N. Adamopoulos, I. Symeonidis, A. Kotsianidis, I.
- Published
- 2021
12. Cumulative pollen concentration curves for pollen allergy diagnosis
- Author
-
Hoffmann, T.M. Travaglini, A. Brighetti, M.A. Acar Şahin, A. Arasi, S. Bregu, B. Caeiro, E. Caglayan Sozmen, S. Charpin, D. Delgado, L. Dimou, M. Fiorilli, M. Fonseca, J.A. Goksel, O. Kalpaklioglu, F. Lame, B. Mazon, A. Mesonjesi, E. Nieto, A. Öztürk, A. Pajno, G. Papadopoulos, N.G. Pellegrini, E. Pereira, A.M. Pereira, M. Pinar, N.M. Pinter, E. Priftanji, A. Sackesen, C. Sfika, I. Suarez, J. Thibaudon, M. Tripodi, S. Ugus, U. Villella, V. Matricardi, P.M. Dramburg, S. the @IT.2020 study team
- Published
- 2021
13. Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease 'sanctuary' during venetoclax treatment?
- Author
-
Dimou, M. Bitsani, A. Roumelioti, M. Dimitrakopoulou, A. Iliakis, T. Pardalis, V. Grafakos, I. Kalyva, S. Markopoulos, A. Kyrtsonis, M.-C. Panayiotidis, P.
- Abstract
Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoclax raises questions on whether the drug penetrates the blood-brain barrier and at what extend, especially in reduced doses given for drug-drug interactions. © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
- Published
- 2021
14. Heterogeneity of pollen food allergy syndrome in seven Southern European countries: the @IT.2020 Multicenter Study
- Author
-
Öztürk, Ayşe Bilge (ORCID 0000-0003-0166-424X & YÖK ID 147629); Saçkesen, Cansın (ORCID 0000-0002-1115-9805 & YÖK ID 182537); Yazıcı, Dilek, Lipp, T.; Acar Şahin, A.; Aggelidis, X.; Arasi, S.; Barbalace, A.; Bourgoin, A.; Bregu, B.; Brighetti, M. A.; Caeiro, E; Çağlayan Sözmen, S.; Caminiti, L.; Charpin, D.; Couto, M.; Delgado, L.; Di Rienzo Businco, A.; Dimier, C.; Dimou, M. V.; Fonseca, J. A. ; Göksel, O.; Güvensen, A.; Hernandez, D.; Hoffmann, T. M.; Jang, D. T.; Kalpaklıoğlu, F.; Lame, B.; Llusar, R.; Makris, M.; Mazon, A.; Mesonjesi, E.; Nieto, A.; Pahus, L.; Pajno, G.; Panasiti, I.; Papadopoulos, N. G.; Pellegrini, E.; Pelosi, S.; Pereira, A. M.; Pereira, M.; Pınar, N. M.; Potapova, E.; Priftanji, A.; Psarros, F.; Sfika, I.; Suarez, J.; Thibaudon, M.; Travaglini, A.; Tripodi, S.; Verdier, V.; Villella, V.; Xepapadaki, P.; Matricardi, P. M.; Dramburg, S., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Öztürk, Ayşe Bilge (ORCID 0000-0003-0166-424X & YÖK ID 147629); Saçkesen, Cansın (ORCID 0000-0002-1115-9805 & YÖK ID 182537); Yazıcı, Dilek, Lipp, T.; Acar Şahin, A.; Aggelidis, X.; Arasi, S.; Barbalace, A.; Bourgoin, A.; Bregu, B.; Brighetti, M. A.; Caeiro, E; Çağlayan Sözmen, S.; Caminiti, L.; Charpin, D.; Couto, M.; Delgado, L.; Di Rienzo Businco, A.; Dimier, C.; Dimou, M. V.; Fonseca, J. A. ; Göksel, O.; Güvensen, A.; Hernandez, D.; Hoffmann, T. M.; Jang, D. T.; Kalpaklıoğlu, F.; Lame, B.; Llusar, R.; Makris, M.; Mazon, A.; Mesonjesi, E.; Nieto, A.; Pahus, L.; Pajno, G.; Panasiti, I.; Papadopoulos, N. G.; Pellegrini, E.; Pelosi, S.; Pereira, A. M.; Pereira, M.; Pınar, N. M.; Potapova, E.; Priftanji, A.; Psarros, F.; Sfika, I.; Suarez, J.; Thibaudon, M.; Travaglini, A.; Tripodi, S.; Verdier, V.; Villella, V.; Xepapadaki, P.; Matricardi, P. M.; Dramburg, S., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
- Abstract
Background: pollen food allergy syndrome (PFAS) is a frequently underdiagnosed disease due to diverse triggers, clinical presentations, and test results. This is especially relevant in geographic areas with a broad spectrum of pollen sensitization, such as Southern Europe. Objectives: to elucidate similarities and differences ofPFAS in nine Southern European centers and identify associated characteristics and unique markers of PFAS. Methods: as part of the @IT.2020 Multicenter Study, 815 patientswith seasonal allergic rhinitis (SAR), aged 10‐60 years, were recruited in seven countries. They completed questionnaires regarding SAR, comorbidities, family history, and PFAS, underwent skin prick testing (SPT) and serum IgE testing. Results: of the 815 patients, 167 (20.5%) reported PFAS reactions.Most commonly, eliciting foods were kiwi (58, 34.7%), peach (43, 25.7%), and melon (26, 15.6%). Reported reactions were mostlylocal (216/319, 67.7%), occurring within five minutes of contact with elicitors (209/319, 65.5%). Associated characteristicsincluded positive IgE to at least one panallergen (profilin, PR‐10, or nsLTP) (p=.007), maternal PFAS (OR:3.716, p=.026), and asthma (OR:1.752, p=.073).Between centers, heterogeneity in prevalence (Marseille: 7.5% vs. Rome: 41.4%, p<.001) and of clinical characteristics was apparent. Cypress played a limited role, with only 1/22 SPT mono‐sensitized patients reporting a food‐reaction (p<.073). Conclusions: PFAS is a frequent comorbidity in Southern European SARpatients. Significant heterogeneity of clinical characteristics in PFAS patients amongst the centers was observed, and may be related to the different pollen sensitization patterns in each geographical area.IgE to panallergen(s), maternal PFAS, and asthma could be PFAS‐associated characteristics., Euroimmun
- Published
- 2021
15. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)
- Author
-
Bousquet, J. Anto, J.M. Iaccarino, G. Czarlewski, W. Haahtela, T. Anto, A. Akdis, C.A. Blain, H. Canonica, G.W. Cardona, V. Cruz, A.A. Illario, M. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Laune, D. Larenas-linnemann, D. Mullol, J. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Latiff, A.H.A. Abdullah, B. Aberer, W. Abusada, N. Adcock, I. Afani, A. Agache, I. Aggelidis, X. Agustin, J. Akdis, C. Akdis, M. Al-Ahmad, M. Bassam, A.A.-Z. Aldrey-Palacios, O. Cuesta, E.A. Alzaabi, A. Amad, S. Ambrocio, G. Annesi-Maesano, I. Ansotegui, I. Anto, J. Arshad, H. Artesani, M.C. Asayag, E. Avolio, F. Azhari, K. Baiardini, I. Bajrović, N. Bakakos, P. Mongono, S.B. Balotro-Torres, C. Barba, S. Barbara, C. Barbosa, E. Barreto, B. Bartra, J. Bateman, E.D. Battur, L. Bedbrook, A. Barajas, M.B. Beghé, B. Bel, E. Kheder, A.B. Benson, M. Berghea, C. Bergmann, K.-C. Bernstein, D. Bewick, M. Bialek, S. Białoszewski, A. Bieber, T. Billo, N. Bilo, M.B. Bindslev-Jensen, C. Bjermer, L. Blain, H. Marciniak, M.B. Bond, C. Boner, A. Bonini, M. Bonini, S. Bosnic-Anticevich, S. Bosse, I. Botskariova, S. Bouchard, J. Boulet, L.-P. Bourret, R. Bousquet, P. Braido, F. Briggs, A. Brightling, C. Brozek, J. Buhl, R. Bumbacea, R. Cabañas, M.T.B. Bush, A. Busse, W.W. Buters, J. Caballero-Fonseca, F. Calderon, M.A. Calvo, M. Camargos, P. Camuzat, T. Cano, A. Capriles-Hulett, A. Caraballo, L. Cardona, V. Carlsen, K.-H. Caro, J. Carr, W. Carreon-Asun-cion, F. Carriazo, A.M. Casale, T. Castor, M.A. Castro, E. Cecchi, L. Sarabia, A.C. Chandrasekharan, R. Chang, Y.-S. Chato-Andeza, V. Chatzi, L. Chatzidaki, C. Chavannes, N.H. Chen, Y. Cheng, L. Chivato, T. Chkhartishvili, E. Christoff, G. Chrystyn, H. Chu, D.K. Chua, A. Chuchalin, A. Chung, K.F. Cicerán, A. Cingi, C. Ciprandi, G. Cirule, I. Coelho, A.C. Constantinidis, J. Sousa, J.C. Costa, E. Costa, D. Domínguez, M.C.C. Coste, A. Cox, L. Cruz, A.A. Cullen, J. Custovic, A. Cvetkovski, B. Czarlewski, W. D’amato, G. Silva, J.D. Dahl, R. Dahlen, S.-E. Daniilidis, V. Nahhas, L.D. Darsow, U. Blay, F. Guia, E.D. Santos, C. Keenoy, E.D.M. Vries, G.D. Deleanu, D. Demoly, P. Denburg, J. Devillier, P. Didier, A. Dimou, M. Dinh-Xuan, A.T. Djukanovic, R. Dokic, D. Silva, M.G.D. Douagui, H. Douladiris, N. Doulaptsi, M. Dray, G. Dubakiene, R. Durham, S. Dykewicz, M. Ebo, D. Edelbaher, N. Eklund, P. El-Gamal, Y. El-Sayed, Z.A. El-Sayed, S.S. El-Seify, M. Emuzyte, R. Enecilla, L. Espinoza, H. Farrell, J. Fernandez, L. Wagner, A.F. Fiocchi, A. Fokkens, W.J. Fontaine, J.-F. Forastiere, F. Fuentes, J.M. Gaerlan–resureccion, E. Gaga, M. Romero, J.L.G. Gamkrelidze, A. Garcia, A. Cobas, C.Y.G. Gayraud, J. Gemicioglu, B. Genova, S. Gereda, J. Wijk, R.G. Gomez, M. Diaz, S.G. Gotua, M. Grigoreas, C. Grisle, I. Guidacci, M. Guldemond, N. Gutter, Z. Guzmán, A. Haahtela, T. Halloum, R. Hamelmann, E. Hammadi, S. Harvey, R. Heinrich, J. Hejjaoui, A. Hellquist-Dahl, B. Velázquez, L.H. Hew, M. Hossny, E. Howarth, P. Hrubiško, M. Villalobos, Y.R.H. Humbert, M. Hyland, M. Iaccarino, G. Ibrahim, M. Illario, M. Ilyina, N. Irani, C. Ispayeva, Z. Ivancevich, J.C. Jares, E. Jarvis, D. Jassem, E. Jenko, K. Uscanga, R.D.J. Johnston, S. Joos, G. Jošt, M. Julge, K. Jung, K.-S. Just, J. Jutel, M. Kaidashev, I. Kalayci, O. Kalyoncu, F. Kapsali, J. Kardas, P. Karjalainen, J. Kasala, C.A. Katotomichelakis, M. Kazi, B. Keil, T. Keith, P. Khaitov, M. Khaltaev, N. Kim, Y.-Y. Kleine-Tebbe, J. Klimek, L. Koffi N’Goran, B. Kompoti, E. Kopač, P. Koppelman, G. Jeverica, A.K. Košnik, M. Kostov, K.V. Kowalski, M.L. Kralimarkova, T. Vrščaj, K.K. Kraxner, H. Kreft, S. Kritikos, V. Kudlay, D. Kull, I. Kuna, P. Kupczyk, M. Kvedariene, V. Kyriakakou, M. Lalek, N. Lane, S. Larenas-Linnemann, D. Latiff, A. Lau, S. Laune, D. Lavrut, J. Le, L. Lessa, M. Levin, M. Li, J. Lieberman, P. Liotta, G. Lipworth, B. Liu, X. Lobo, R. Lodrup Carlsen, K.C. Lombardi, C. Louis, R. Loukidis, S. Lourenço, O. Luna Pech, J.A. Madjar, B. Magnan, A. Mahboub, B. Mair, A. Mais, Y. van der Zee, A.-H.M. Makela, M. Makris, M. Malling, H.-J. Mandajieva, M. Manning, P. Manousakis, M. Maragoudakis, P. Marshall, G. Martins, P. Masjedi, M.R. Máspero, J.F. Campos, J.J.M. Maurer, M. Mavale-Manuel, S. Meço, C. Melén, E. Melo-Gomes, E. Meltzer, E.O. Menditto, E. Menzies-Gow, A. Merk, H. Michel, J.-P. Miculinic, N. Midão, L. Mihaltan, F. Mikael, K. Mikos, N. Milenkovic, B. Mitsias, D. Moalla, B. Moda, G. Martínez, M.D.M. Mohammad, Y. Moin, M. Molimard, M. Momas, I. Monaco, A. Montefort, S. Mora, D. Morais-Almeida, M. Mösges, R. Mostafa, B.E. Mullol, J. Münter, L. Muraro, A. Murray, R. Mustakov, T. Naclerio, R. Nadif, R. Nakonechna, A. Namazova-Baranova, L. Navarro-Locsin, G. Neffen, H. Nekam, K. Neou, A. Nicod, L. Niederberger-Leppin, V. Niedoszytko, M. Nieto, A. Novellino, E. Nunes, E. Nyembue, D. O’hehir, R. Odjakova, C. Ohta, K. Okamoto, Y. Okubo, K. Oliver, B. Onorato, G.L. Orru, M.P. Ouédraogo, S. Ouoba, K. Paggiaro, P.L. Pagkalos, A. Palaniappan, S.P. Pali-Schöll, I. Palkonen, S. Palmer, S. Bunu, C.P. Panzner, P. Papadopoulos, N.G. Papanikolaou, V. Papi, A. Paralchev, B. Paraskevopoulos, G. Park, H.S. Passalacqua, G. Patella, V. Pavord, I. Pawankar, R. Pedersen, S. Peleve, S. Pereira, A. Pérez, T. Pfaar, O. Pham-Thi, N. Pigearias, B. Pin, I. Piskou, K. Pitsios, C. Pitsios, K. Plavec, D. Poethig, D. Pohl, W. Susic, A.P. Popov, T.A. Portejoie, F. Potter, P. Poulsen, L. Prados-Torres, A. Prarros, F. Price, D. Prokopakis, E. Puy, R. Rabe, K. Raciborski, F. Ramos, J. Recto, M.T. Reda, S.M. Regateiro, F. Reider, N. Reitsma, S. Repka-Ramirez, S. Rimmer, J. Yeverino, D.R. Rizzo, J.A. Robalo-Cordeiro, C. Roberts, G. Roche, N. González, M.R. Zagal, E.R. Rolland, C. Roller-Wirns-berger, R. Rodriguez, M.R. Romano, A. Rombaux, P. Romualdez, J. Rosado-Pinto, J. Rosario, N. Rosenwasser, L. Rottem, M. Rouadi, P. Rovina, N. Sinur, I.R. Ruiz, M. Segura, L.T.R. Ryan, D. Sagara, H. Sakai, D. Sakurai, D. Saleh, W. Salimaki, J. Salina, H. Samitas, K.-N. Coronel, M.G.S. Sanchez-Borges, M. Sanchez-Lopez, J. Sarafoleanu, C. Serpa, F.S. Sastre-Dominguez, J. Scadding, G. Scheire, S. Schmid-Grendelmeier, P. Schuhl, J.F. Schunemann, H. Schvalbová, M. Scichilone, N. Sepúlveda, C. Serrano, E. Sheikh, A. Shields, M. Shishkov, V. Siafakas, N. Simeonov, A. Simons, E.F. Sisul, J.C. Sitkauskiene, B. Skrindo, I. Soklič, T. Solé, D. Sooronbaev, T. Soto-Martinez, M. Sova, M. Spertini, F. Spranger, O. Stamataki, S. Stefanaki, L. Stellato, C. Stelmach, R. Sterk, P. Strandberg, T. Stute, P. Subramaniam, A. Ulrik, C.S. Sutherland, M. Sylvestre, S. Syrigou, A. Barata, L.T. Takovska, N. Tan, R. Tan, F. Tan, V. Tang, I.P. Taniguchi, M. Tannert, L. Tattersall, J. Teixeira, M.D.C. Thijs, C. Thomas, M. To, T. Todo-Bom, A.M. Togias, A. Tomazic, P.-V. Toppila-Salmi, S. Toskala, E. Triggiani, M. Triller, N. Triller, K. Tsiligianni, I. Ulmeanu, R. Urbancic, J. Pereira, M.U. Vachova, M. Valdés, F. Valenta, R. Rostan, M.V. Valero, A. Valiulis, A. Vallianatou, M. Valovirta, E. Eerd, M.V. Ganse, E.V. Hage, M. Vandenplas, O. Vasankari, T. Vassileva, D. Ventura, M.T. Vera-Munoz, C. Vicheva, D. Vichyanond, P. Vidgren, P. Viegi, G. Vogelmeier, C. Hertzen, L.V. Vontetsianos, T. Vourdas, D. Wagenmann, M. Walker, S. Wallace, D. Wang, D.Y. Waserman, S. Wickman, M. Williams, S. Williams, D. Wilson, N. Woo, K. Wright, J. Wroczynski, P. Xepapadaki, P. Yakovliev, P. Yamaguchi, M. Yan, K. Yap, Y.Y. Yawn, B. Yiallouros, P. Yorgancioglu, A. Yoshihara, S. Young, I. Yusuf, O.B. Zaidi, A. Zaitoun, F. Zar, H. Zernotti, M. Zhang, L. Zhong, N. Zidarn, M. Zuberbier, T.
- Abstract
Following publication of the original article [1], the authors identified an error in the affiliation list. The affiliation of author G. Walter Canonica should have been split up into two affiliations: • Personalized Medicine, Asthma and Allergy – Humanitas Clinical and Research Center – IRCCS, Rozzano (MI), Italy • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy The corrected affiliation list is reflected in this Correction. © 2020, The Author(s).
- Published
- 2020
16. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
- Author
-
Papageorgiou, S.G. Kotsianidis, I. Bouchla, A. Symeonidis, A. Galanopoulos, A. Viniou, N.-A. Hatzimichael, E. Vassilakopoulos, T.P. Gogos, D. Megalakaki, A. Zikos, P. Diamantopoulos, P. Kourakli, A. Giannoulia, P. Papoutselis, M. Poulakidas, E. Arapaki, M. Vardi, A. Anagnostopoulos, A. Mparmparousi, D. Papaioannou, M. Bouronikou, E. Dimou, M. Papadaki, H. Panayiotidis, P. Pappa, V.
- Subjects
urologic and male genital diseases ,neoplasms - Abstract
Background: 5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied. Methods: This study of the Hellenic MDS Study Group included 687 consecutive patients with higher-risk MDS and oligoblastic AML treated with 5-AZA. Results: The International Prognostic Scoring System (IPSS) revised version (IPSS-R), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 or 1 versus ⩾2) and baseline serum ferritin (SF) levels > 520 ng/ml were shown to independently predict response to 5-AZA. In the survival analysis, the IPSS and IPSS-R risk classification systems along with the ECOG PS and SF levels > 520 ng/ml proved to be independent prognosticators for overall survival (OS), as well as for leukemia-free survival (LFS). Next, we built new multivariate models for OS and LFS, incorporating only ECOG PS and SF levels besides IPSS or IPSS-R risk classification systems. Thereby, the new modified IPSS and IPSS-R risk classification systems (H-PSS, H-PSS-R) could each discriminate a low, an intermediate and a high-risk patient group regarding OS and LFS. The H-PSS and H-PSS-R proved to be better predictors of OS than their previous counterparts as well as the French prognostic score, while the most powerful OS predictor was the new, H-PSS-R system. Conclusions: ECOG PS and SF levels > 520 ng/ml independently predict response to 5-AZA, OS and LFS. Their incorporation in the IPSS and IPSS-R scores enhances these scores’ predictive power in 5-AZA-treated higher-risk MDS and oligoblastic AML patients. © The Author(s), 2020.
- Published
- 2020
17. Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin-lymphoma
- Author
-
Asimakopoulos, J.V. Angelopoulou, M.K. Arapaki, M.-P. Kanellopoulos, A. Dimou, M. Giakoumis, X. Konstantinou, E. Belia, M. Chatzidimitriou, C. Sachanas, S. Iliakis, T. Kyrtsonis, M.-C. Siakantaris, M.P. Viniou, N.-A. Variamis, E. Kontopidou, F.N. Pangalis, G.A. Panayiotidis, P. Konstantopoulos, K. Vassilakopoulos, T.P.
- Published
- 2020
18. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry
- Author
-
Diamantopoulos, P.T. Pappa, V. Symeonidis, A. Kotsianidis, I. Galanopoulos, A. Papadaki, H. Anagnostopoulos, A. Vassilopoulos, G. Zikos, P. Hatzimichael, E. Papaioannou, M. Megalakaki, A. Kotsopoulou, M. Repousis, P. Dimou, M. Solomou, E. Pontikoglou, C. Kyriakakis, G. Tsokanas, D. Papoutselis, M.-K. Papageorgiou, S. Kourakli, A. Panayiotidis, P. Viniou, N.-A.
- Abstract
Background: Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible treatment goal. Patients and Methods: We analyzed data from patients with MDS treated with 5-azacytidine recorded in the Hellenic 5-azacytidine registry. We divided patients, on the basis of their survival after 5-azacytidine initiation (OST), in groups of long-term survivors (Q3 and P90 group with OST above the third quartile and the 90th percentile of the whole group, respectively) and short-term survivors comprising the remaining patients, and compared the characteristics between the groups. The study included 626 patients, 157 in the Q3 group and 63 in the P90 group. Results: Categorization per the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), and World Health Organization–based prognostic scoring system (WPSS) was found to predict long-term survival, while multivariate analysis revealed that response to 5-azacytidine was the strongest predictor of long-term survival. Nevertheless, patients with hematologic improvement (HI) and stable disease (SD) were equally distributed in the groups of short- and long-term survival. Conclusion: SD should not be considered a poor treatment response and should not be grouped with failure, while HI offers similar prognosis to SD and thus should not be grouped with complete and partial remission. Patients with SD should continue treatment with 5-azacytidine. The prognosis of myelodysplastic syndrome (MDS) has changed since the introduction of hypomethylating agents that offer the potential for long-term survival. We studied the characteristics of long-term survival in a cohort of 626 patients with MDS treated with 5-azacytidine; response was found to be the single most important predictive factor of long-term survival, while stable disease (SD) and hematologic improvement were equally distributed in the groups with long- and short-term survival. Achieving SD has prognostic significance, and SD should not be grouped with treatment failure. © 2019 Elsevier Inc.
- Published
- 2020
19. Frontline treatment with the combination obinutuzumab±chlorambucil for chronic lymphocytic leukemia outside clinical trials: results of a multinational, multicenter study by ERIC and the Israeli CLL study group
- Author
-
Herishanu Y, Shaulov A, Fineman R, BasiC-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Ciocan O, Doubek M, Shvidel L, Dali N, Miras F, De Meuter A, Dimou M, Mauro F, Coscia M, Bumbea H, Szasz R, Tadmor T, Gutwein O, Gentile M, Scarfo L, Tedeschi A, Sportoletti P, Vazquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin G, Loscertales J, Perez A, Nijziel M, Popov V, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, and Ghia P
- Abstract
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O±Clb in unfit patients with CLL, in a "real-world" setting. Patients with documented del(17p13.1)/TP53mutation were excluded. A total of 437 patients (median age, 75.9years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min)were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95%CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del(11q22.3) and/or IGHV-unmutated], lymph nodes of diameter >5cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a "real-world" setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del(11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease. This article is protected by copyright. All rights reserved.
- Published
- 2020
20. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
- Author
-
Dreyling, M. Santoro, A. Mollica, L. Leppä, S. Follows, G. Lenz, G. Kim, W.S. Nagler, A. Dimou, M. Demeter, J. Özcan, M. Kosinova, M. Bouabdallah, K. Morschhauser, F. Stevens, D.A. Trevarthen, D. Munoz, J. Rodrigues, L. Hiemeyer, F. Miriyala, A. Garcia-Vargas, J. Childs, B.H. Zinzani, P.L.
- Abstract
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with histologically confirmed indolent B-cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression-free survival, and overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively. Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors. © 2019 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.
- Published
- 2020
21. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)
- Author
-
Bousquet, J., Anto, J. M., Iaccarino, G., Czarlewski, W., Haahtela, T., Anto, A., Akdis, C. A., Blain, H., Canonica, G. W., Cardona, V., Cruz, A. A., Illario, M., Ivancevich, J. C., Jutel, M., Klimek, L., Kuna, P., Laune, D., Larenas-linnemann, D., Mullol, J., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Latiff, A. H. A., Abdullah, B., Aberer, W., Abusada, N., Adcock, I., Afani, A., Agache, I., Aggelidis, X., Agustin, J., Akdis, C., Akdis, M., Al-Ahmad, M., Bassam, A. A. -Z., Aldrey-Palacios, O., Cuesta, E. A., Alzaabi, A., Amad, S., Ambrocio, G., Annesi-Maesano, I., Ansotegui, I., Anto, J., Arshad, H., Artesani, M. C., Asayag, E., Avolio, F., Azhari, K., Baiardini, I., Bajrovic, N., Bakakos, P., Mongono, S. B., Balotro-Torres, C., Barba, S., Barbara, C., Barbosa, E., Barreto, B., Bartra, J., Bateman, E. D., Battur, L., Bedbrook, A., Barajas, M. B., Beghe, B., Bel, E., Kheder, A. B., Benson, M., Berghea, C., Bergmann, K. -C., Bernstein, D., Bewick, M., Bialek, S., Bialoszewski, A., Bieber, T., Billo, N., Bilo, M. B., Bindslev-Jensen, C., Bjermer, L., Marciniak, M. B., Bond, C., Boner, A., Bonini, M., Bonini, S., Bosnic-Anticevich, S., Bosse, I., Botskariova, S., Bouchard, J., Boulet, L. -P., Bourret, R., Bousquet, P., Braido, F., Briggs, A., Brightling, C., Brozek, J., Buhl, R., Bumbacea, R., Cabanas, M. T. B., Bush, A., Busse, W. W., Buters, J., Caballero-Fonseca, F., Calderon, M. A., Calvo, M., Camargos, P., Camuzat, T., Cano, A., Capriles-Hulett, A., Caraballo, L., Carlsen, K. -H., Caro, J., Carr, W., Carreon-Asun-cion, F., Carriazo, A. M., Casale, T., Castor, M. A., Castro, E., Cecchi, L., Sarabia, A. C., Chandrasekharan, R., Chang, Y. -S., Chato-Andeza, V., Chatzi, L., Chatzidaki, C., Chavannes, N. H., Chen, Y., Cheng, L., Chivato, T., Chkhartishvili, E., Christoff, G., Chrystyn, H., Chu, D. K., Chua, A., Chuchalin, A., Chung, K. F., Ciceran, A., Cingi, C., Ciprandi, G., Cirule, I., Coelho, A. C., Constantinidis, J., Sousa, J. C., Costa, E., Costa, D., Dominguez, M. C. C., Coste, A., Cox, L., Cullen, J., Custovic, A., Cvetkovski, B., D'Amato, G., Silva, J. D., Dahl, R., Dahlen, S. -E., Daniilidis, V., Nahhas, L. D., Darsow, U., Blay, F., Guia, E. D., Santos, C., Keenoy, E. D. M., Vries, G. D., Deleanu, D., Demoly, P., Denburg, J., Devillier, P., Didier, A., Dimou, M., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Silva, M. G. D., Douagui, H., Douladiris, N., Doulaptsi, M., Dray, G., Dubakiene, R., Durham, S., Dykewicz, M., Ebo, D., Edelbaher, N., Eklund, P., El-Gamal, Y., El-Sayed, Z. A., El-Sayed, S. S., El-Seify, M., Emuzyte, R., Enecilla, L., Espinoza, H., Farrell, J., Fernandez, L., Wagner, A. F., Fiocchi, A., Fokkens, W. J., Fontaine, J. -F., Forastiere, F., Fuentes, J. M., Gaerlan-resureccion, E., Gaga, M., Romero, J. L. G., Gamkrelidze, A., Garcia, A., Cobas, C. Y. G., Gayraud, J., Gemicioglu, B., Genova, S., Gereda, J., Wijk, R. G., Gomez, M., Diaz, S. G., Gotua, M., Grigoreas, C., Grisle, I., Guidacci, M., Guldemond, N., Gutter, Z., Guzman, A., Halloum, R., Hamelmann, E., Hammadi, S., Harvey, R., Heinrich, J., Hejjaoui, A., Hellquist-Dahl, B., Velazquez, L. H., Hew, M., Hossny, E., Howarth, P., Hrubisko, M., Villalobos, Y. R. H., Humbert, M., Hyland, M., Ibrahim, M., Ilyina, N., Irani, C., Ispayeva, Z., Jares, E., Jarvis, D., Jassem, E., Jenko, K., Uscanga, R. D. J., Johnston, S., Joos, G., Jost, M., Julge, K., Jung, K. -S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, F., Kapsali, J., Kardas, P., Karjalainen, J., Kasala, C. A., Katotomichelakis, M., Kazi, B., Keil, T., Keith, P., Khaitov, M., Khaltaev, N., Kim, Y. -Y., Kleine-Tebbe, J., Koffi N'Goran, B., Kompoti, E., Kopac, P., Koppelman, G., Jeverica, A. K., Kosnik, M., Kostov, K. V., Kowalski, M. L., Kralimarkova, T., Vrscaj, K. K., Kraxner, H., Kreft, S., Kritikos, V., Kudlay, D., Kull, I., Kupczyk, M., Kvedariene, V., Kyriakakou, M., Lalek, N., Lane, S., Larenas-Linnemann, D., Latiff, A., Lau, S., Lavrut, J., Le, L., Lessa, M., Levin, M., Li, J., Lieberman, P., Liotta, G., Lipworth, B., Liu, X., Lobo, R., Lodrup Carlsen, K. C., Lombardi, C., Louis, R., Loukidis, S., Lourenco, O., Luna Pech, J. A., Madjar, B., Magnan, A., Mahboub, B., Mair, A., Mais, Y., van der Zee, A. -H. M., Makela, M., Makris, M., Malling, H. -J., Mandajieva, M., Manning, P., Manousakis, M., Maragoudakis, P., Marshall, G., Martins, P., Masjedi, M. R., Maspero, J. F., Campos, J. J. M., Maurer, M., Mavale-Manuel, S., Meco, C., Melen, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Menzies-Gow, A., Merk, H., Michel, J. -P., Miculinic, N., Midao, L., Mihaltan, F., Mikael, K., Mikos, N., Milenkovic, B., Mitsias, D., Moalla, B., Moda, G., Martinez, M. D. M., Mohammad, Y., Moin, M., Molimard, M., Momas, I., Monaco, A., Montefort, S., Mora, D., Morais-Almeida, M., Mosges, R., Mostafa, B. E., Munter, L., Muraro, A., Murray, R., Mustakov, T., Naclerio, R., Nadif, R., Nakonechna, A., Namazova-Baranova, L., Navarro-Locsin, G., Neffen, H., Nekam, K., Neou, A., Nicod, L., Niederberger-Leppin, V., Niedoszytko, M., Nieto, A., Novellino, E., Nunes, E., Nyembue, D., O'Hehir, R., Odjakova, C., Ohta, K., Okamoto, Y., Okubo, K., Oliver, B., Onorato, G. L., Orru, M. P., Ouedraogo, S., Ouoba, K., Paggiaro, P. L., Pagkalos, A., Palaniappan, S. P., Pali-Scholl, I., Palkonen, S., Palmer, S., Bunu, C. P., Panzner, P., Papanikolaou, V., Papi, A., Paralchev, B., Paraskevopoulos, G., Park, H. S., Passalacqua, G., Patella, V., Pavord, I., Pawankar, R., Pedersen, S., Peleve, S., Pereira, A., Perez, T., Pham-Thi, N., Pigearias, B., Pin, I., Piskou, K., Pitsios, C., Pitsios, K., Plavec, D., Poethig, D., Pohl, W., Susic, A. P., Popov, T. A., Portejoie, F., Potter, P., Poulsen, L., Prados-Torres, A., Prarros, F., Price, D., Prokopakis, E., Puy, R., Rabe, K., Raciborski, F., Ramos, J., Recto, M. T., Reda, S. M., Regateiro, F., Reider, N., Reitsma, S., Repka-Ramirez, S., Rimmer, J., Yeverino, D. R., Rizzo, J. A., Robalo-Cordeiro, C., Roberts, G., Roche, N., Gonzalez, M. R., Zagal, E. R., Rolland, C., Roller-Wirns-berger, R., Rodriguez, M. R., Romano, A., Rombaux, P., Romualdez, J., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Rouadi, P., Rovina, N., Sinur, I. R., Ruiz, M., Segura, L. T. R., Ryan, D., Sagara, H., Sakai, D., Sakurai, D., Saleh, W., Salimaki, J., Salina, H., Samitas, K. -N., Coronel, M. G. S., Sanchez-Borges, M., Sanchez-Lopez, J., Sarafoleanu, C., Serpa, F. S., Sastre-Dominguez, J., Scadding, G., Scheire, S., Schmid-Grendelmeier, P., Schuhl, J. F., Schunemann, H., Schvalbova, M., Scichilone, N., Sepulveda, C., Serrano, E., Sheikh, A., Shields, M., Shishkov, V., Siafakas, N., Simeonov, A., Simons, E. F., Sisul, J. C., Sitkauskiene, B., Skrindo, I., Soklic, T., Sole, D., Sooronbaev, T., Soto-Martinez, M., Sova, M., Spertini, F., Spranger, O., Stamataki, S., Stefanaki, L., Stellato, C., Stelmach, R., Sterk, P., Strandberg, T., Stute, P., Subramaniam, A., Ulrik, C. S., Sutherland, M., Sylvestre, S., Syrigou, A., Barata, L. T., Takovska, N., Tan, R., Tan, F., Tan, V., Tang, I. P., Taniguchi, M., Tannert, L., Tattersall, J., Teixeira, M. D. C., Thijs, C., Thomas, M., To, T., Todo-Bom, A. M., Togias, A., Tomazic, P. -V., Toppila-Salmi, S., Toskala, E., Triggiani, M., Triller, N., Triller, K., Tsiligianni, I., Ulmeanu, R., Urbancic, J., Pereira, M. U., Vachova, M., Valdes, F., Valenta, R., Rostan, M. V., Valero, A., Vallianatou, M., Valovirta, E., Eerd, M. V., Ganse, E. V., Hage, M., Vandenplas, O., Vasankari, T., Vassileva, D., Ventura, M. T., Vera-Munoz, C., Vicheva, D., Vichyanond, P., Vidgren, P., Viegi, G., Vogelmeier, C., Hertzen, L. V., Vontetsianos, T., Vourdas, D., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Wickman, M., Williams, S., Williams, D., Wilson, N., Woo, K., Wright, J., Wroczynski, P., Xepapadaki, P., Yakovliev, P., Yamaguchi, M., Yan, K., Yap, Y. Y., Yawn, B., Yiallouros, P., Yoshihara, S., Young, I., Yusuf, O. B., Zaidi, A., Zaitoun, F., Zar, H., Zernotti, M., Zhang, L., Zhong, N., and Zidarn, M.
- Published
- 2020
22. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- Author
-
Scarfo, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernandez-Rivas, JA, Miras, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuellar-Garcia, C, Itchaki, G, Spacek, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Simkovic, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foa, R, Cuneo, A, Ghia, P, Scarfo, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernandez-Rivas, JA, Miras, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuellar-Garcia, C, Itchaki, G, Spacek, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Simkovic, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foa, R, Cuneo, A, and Ghia, P
- Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
- Published
- 2020
23. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
- Author
-
Herishanu, Y., Shaulov, A., Fineman, R., Basic-Kinda, S., Aviv, A., Wasik-Szczepanek, E., Jaksic, O., Zdrenghea, M., Greenbaum, U., Mandac, I., Simkovic, M., Morawska, M., Benjamini, O., Spacek, M., Nemets, A., Bairey, O., Trentin, L., Ruchlemer, R., Laurenti, Luca, Stanca Ciocan, O., Doubek, M., Shvidel, L., Dali, N., Miras, F., De Meuter, A., Dimou, M., Mauro, F. R., Coscia, M., Bumbea, H., Szasz, R., Tadmor, T., Gutwein, O., Gentile, Marino, Scarfo, L., Tedeschi, Alessandra, Sportoletti, P., Gimeno Vazquez, E., Marquet, J., Assouline, S., Papaioannou, M., Braester, A., Levato, L., Gregor, M., Rigolin, G. M., Loscertales, J., Medina Perez, A., Nijziel, M. R., Popov, V. M., Collado, R., Slavutsky, I., Itchaki, G., Ringelstein, S., Goldschmidt, N., Perry, C., Levi, S., Polliack, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Tedeschi A., Herishanu, Y., Shaulov, A., Fineman, R., Basic-Kinda, S., Aviv, A., Wasik-Szczepanek, E., Jaksic, O., Zdrenghea, M., Greenbaum, U., Mandac, I., Simkovic, M., Morawska, M., Benjamini, O., Spacek, M., Nemets, A., Bairey, O., Trentin, L., Ruchlemer, R., Laurenti, Luca, Stanca Ciocan, O., Doubek, M., Shvidel, L., Dali, N., Miras, F., De Meuter, A., Dimou, M., Mauro, F. R., Coscia, M., Bumbea, H., Szasz, R., Tadmor, T., Gutwein, O., Gentile, Marino, Scarfo, L., Tedeschi, Alessandra, Sportoletti, P., Gimeno Vazquez, E., Marquet, J., Assouline, S., Papaioannou, M., Braester, A., Levato, L., Gregor, M., Rigolin, G. M., Loscertales, J., Medina Perez, A., Nijziel, M. R., Popov, V. M., Collado, R., Slavutsky, I., Itchaki, G., Ringelstein, S., Goldschmidt, N., Perry, C., Levi, S., Polliack, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., and Tedeschi A.
- Abstract
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a “real-world” setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a “real-world” setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
- Published
- 2020
24. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- Author
-
Scarfo, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, Luca, Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, Marino, Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, Dario, Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Rossi D., Foa R., Scarfo, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, Luca, Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, Marino, Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, Dario, Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Rossi D., and Foa R.
- Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
- Published
- 2020
25. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib
- Author
-
Georgiou, G, Efthymiou, A, Vardounioti, I, Boutsikas, G, Angelopoulou, M K, Vassilakopoulos, T P, Kyrtsonis, M-C, Plata, E, Tofas, P, Bitsani, A, Bartzi, V, Pessach, I, Dimou, M, and Panayiotidis, P
- Published
- 2012
- Full Text
- View/download PDF
26. The cytoplasmic cyclophilin negatively affects bacterial swarming motility and biofilm formation ability: P27-94
- Author
-
Dimou, M., Zografou, C., Skagia, A., Vezyri, E., Venieraki, A., and Katinakis, P.
- Published
- 2012
27. Introduction
- Author
-
LACOUR, Claude, DIMOU, M., and PSYCHATIS, Y.
- Published
- 2019
28. Low Bone Mineral Density and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
- Author
-
Anargyrou, K. Fotiou, D. Vassilakopoulos, T.P. Christoulas, D. Makras, P. Dimou, M. Ntanasis-Stathopoulos, I. Masouridou, S. Angelopoulou, M.K. Papatheodorou, A. Tsionos, K. Panayiotidis, P. Dimopoulos, M.A. Terpos, E.
- Subjects
musculoskeletal diseases - Abstract
Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorates quality of life. There are very limited data in the literature for the effect of chemotherapy on bone metabolism of adult patients with Non-Hodgkin Lymphoma (NHL). We prospectively evaluated bone remodeling pre- and post-chemotherapy in 61 patients with newly diagnosed NHL. First-line chemotherapy resulted in high bone turnover, which led to increased bone loss and reduced bone mineral density (BMD) of lumbar spine (L1-L4) and femur neck (FN). The reduction of L1-L4 and FN BMD post-chemo was more profound in males and in older patients (>55 years). Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 and FN BMD as compared to 6 cycles. The administration of chemotherapy also resulted in a dramatic increase of bone resorption markers (CTX and TRACP-5b), bone formation markers, (bALP and Osteocalcin) and of osteoblast regulator Dickkopf-1. During study period, one patient had a pathological fracture in his right FN. © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
- Published
- 2019
29. Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact
- Author
-
Baliakas, P. Jeromin, S. Iskas, M. Puiggros, A. Plevova, K. Nguyen-Khac, F. Davis, Z. Matteo Rigolin, G. Visentin, A. Xochelli, A. Delgado, J. Baran-Marszak, F. Stalika, E. Abrisqueta, P. Durechova, K. Papaioannou, G. Eclache, V. DImou, M. Iliakis, T. Collado, R. Doubek, M. Calasanz, M.J. Ruiz-Xiville, N. Moreno, C. Jarosova, M. Leeksma, A.C. Panayiotidis, P. Podgornik, H. Cymbalista, F. Anagnostopoulos, A. Trentin, L. Stavroyianni, N. Davi, F. Ghia, P. Kater, A.P. Cuneo, A. Pospisilova, S. Espinet, B. Athanasiadou, A. Oscier, D. Haferlach, C. Stamatopoulos, K. on behalf of ERIC, the European Research Initiative on CLL
- Abstract
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosomebanding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and +12,+19 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hypermutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with +12,+19, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with ≥5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL. © 2019 by The American Society of Hematology.
- Published
- 2019
30. L’Odyssée revisitée, le retour de Circé
- Author
-
LACOUR, Claude, DIMOU, M., and PSYCHARIS, Y.
- Published
- 2019
31. Chronic myelomonocytic leukemia treated with 5-azacytidine–results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system
- Author
-
Diamantopoulos, P.T. Kotsianidis, I. Symeonidis, A. Pappa, V. Galanopoulos, A. Gogos, D. Karakatsanis, S. Papadaki, H. Palla, A. Hatzimichael, E. Dimou, M. Papageorgiou, S. Delimpasis, S. Papaioannou, M. Papoutselis, M. Kourakli, A. Tsokanas, D. Anagnostopoulos, A. Kontos, C.K. Panayiotidis, P. Viniou, N.-A. On behalf of the Hellenic MDS study group
- Subjects
hemic and lymphatic diseases - Abstract
Hypomethylating agents are widely used in chronic myelomonocytic leukemia (CMML). We analyzed the characteristics of 88 patients with CMML homogeneously treated with 5-azacytidine (Hellenic 5-Azacytidine Registry). The overall response rate was 48.9% and the median overall survival (OS) 29.7 months. Out of the seven most widely used prognostic scoring systems for CMML, the Dusseldorf score (DUSS) showed the best prognostic capability (HR, 2.27; p
- Published
- 2019
32. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry
- Author
-
Diamantopoulos, P. Koumbi, D. Kotsianidis, I. Pappa, V. Symeonidis, A. Galanopoulos, A. Zikos, P. Papadaki, H.A. Panayiotidis, P. Dimou, M. Hatzimichael, E. Vassilopoulos, G. Delimpasis, S. Mparmparousi, D. Papageorgiou, S. Variami, E. Kyrtsonis, M.-C. Megalakaki, A. Kotsopoulou, M. Repousis, P. Adamopoulos, I. Kontopidou, F. Christoulas, D. Kourakli, A. Tsokanas, D. Konstantinos Papoutselis, M. Kyriakakis, G. Viniou, N.-A. the Hellenic MDS study group
- Abstract
In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised International Prognostic Scoring System (IPSS-R). To further characterize the prognostic significance of chromosome 17 abnormalities we analyzed the hematologic and prognostic characteristics of 548 adult patients with MDS treated with 5-azacytidine through the Hellenic 5-azacytidine registry and found 32 patients with a chromosome 17 abnormality (6 with i[17q], 15 with -17, 3 with add[17p] and the rest with other rarer abnormalities, mostly translocations). The presence of a chromosome 17 abnormality was correlated with poor prognostic features (high IPSS, IPSS-R, and WPSS scores) and a low overall survival rate (15.7 vs 36.4 months for patients without chromosome 17 abnormalities, Kaplan–Meier, Log Rank P
- Published
- 2019
33. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
- Author
-
Baliakas, P, Jeromin, S, Iskas, M, Puiggros, A, Plevova, K, Nguyen-Khac, F, Davis, Z, Rigolin, GM, Visentin, A, Xochelli, A, Delgado, J, Baran-Marszak, F, Stalika, E, Abrisqueta, P, Durechova, K, Papaioannou, G, Eclache, V, Dimou, M, Iliakis, T, Collado, R, Doubek, M, Calasanz, MJ, Ruiz-Xiville, N, Moreno, C, Jarosova, M, Leeksma, AC, Panayiotidis, P, Podgornik, H, Cymbalista, F, Anagnostopoulos, A, Trentin, L, Stavroyianni, N, Davi, F, Ghia, P, Kater, AP, Cuneo, A, Pospisilova, S, Espinet, B, Athanasiadou, A, Oscier, D, Haferlach, C, Stamatopoulos, K, and ERIC European Res Initiative CLL
- Abstract
Recent evidence suggests that complex karyotype (CK) defined by the presence of >= 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with >= 5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and 112,119 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hyper-mutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with 112,119, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with >= 5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.
- Published
- 2019
34. L'Odyssée revisitée, le retour de Circé, Réflexions sur le colloque ASRDLF, Athènes 2017
- Author
-
Lacour, Claude, Dimou, M., Psycharis, Y., Admin, Oskar, Groupe de Recherche en Economie Théorique et Appliquée (GREThA), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), and Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[QFIN]Quantitative Finance [q-fin] ,[QFIN] Quantitative Finance [q-fin] - Published
- 2019
35. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome
- Author
-
Diamantopoulos, P.T. Kontandreopoulou, C.-N. Symeonidis, A. Kotsianidis, I. Pappa, V. Galanopoulos, A. Vassilakopoulos, T. Dimou, M. Solomou, E. Kyrtsonis, M.-C. Siakantaris, M. Angelopoulou, M. Kourakli, A. Papageorgiou, S. Christopoulou, G. Roumelioti, M. Panayiotidis, P. Viniou, N.-A. On behalf of the Hellenic MDS Study Group
- Abstract
Poly (ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme that participates in the DNA repair of malignant cells, with various consequences on their survival. We have recently shown that PARP1 mRNA levels in the bone marrow of patients with myelodysplastic syndrome (MDS) are correlated to prognosis. To evaluate PARP1 as a biomarker of response to 5-azacytidine in patients with MDS, we measured PARP1 mRNA levels by a quantitative real-time PCR in diagnostic bone marrow samples of 77 patients with MDS treated with 5-azacytidine. Patients with higher PARP1 mRNA levels had a better response to 5-azacytidine per the IWG criteria (p = 0.006) and a longer median survival after 5-azacytidine initiation (p = 0.033). Multivariate analysis revealed that PARP1 mRNA level was the only factor affecting response to treatment and survival after treatment with 5-azacytidine. A next-generation sequencing for 40 genes of interest in MDS and quantification of the methylation levels of the PARP1 promoter were also carried out in a subset of samples (16 and 18 samples respectively). It is the first time that a single, easily measurable biomarker shows a clear correlation with response to treatment and survival in a patient population consisting of previously untreated patients with MDS homogeneously treated with 5-azacytidine. The fact that PARP1 is also a treatment target in several malignancies underscores the importance of our finding for the potential use of PARP1 inhibitors in MDS. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2019
36. Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
- Author
-
Pleyer, L, Leisch, M, Kourakli, A, Padron, E, Maciejewski, JP, Xicoy, B, Kaivers, J, Ungerstedt, J, Heibl, S, Patiou, P, Hunter, AM, Mora, E, Geissler, K, Dimou, M, Jimenez, MJ, Kiesl, D, Viniou, NA, Patel, BJ, Sangerman, MA, Valent, P, Roubakis, C, del Castillo, TB, Galanopoulos, A, Calabuig, M, Bonadies, N, de Almeida, AM, Cermak, J, Jerez, A, Montoro, J, Cortes, A, Pita, AA, Andrade, BL, Lindberg, EH, Germing, U, Sekeres, MA, List, AF, Symeonidis, A, Sanz, GF, and Greil, R
- Published
- 2019
37. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
- Author
-
Angelopoulou, M.K. Vassilakopoulos, T.P. Batsis, I. Sakellari, I. Gkirkas, K. Pappa, V. Giannoulia, P. Apostolidis, I. Apostolopoulos, C. Roussou, P. Panayiotidis, P. Dimou, M. Kyrtsonis, M.-C. Palassopoulou, M. Vassilopoulos, G. Moschogiannis, M. Kalpadakis, C. Margaritis, D. Spyridonidis, A. Michalis, E. Anargyrou, K. Repousis, P. Hatzimichael, E. Bousiou, Z. Poulakidas, E. Grentzelias, D. Harhalakis, N. Pangalis, G.A. Anagnostopoulos, A. Tsirigotis, P.
- Abstract
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P =.005). Bulky disease (P =.01) and response to BV (P
- Published
- 2018
38. High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine
- Author
-
Dimou, M. Roumelioti, M. Dimitrakopoulou, A. Bitsani, C. Kotsanti, S. Petsa, P. Papaioannou, P. Kyrtsonis, M.-C. Panayiotidis, P.
- Published
- 2018
39. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
- Author
-
Rinaldetti, S. Pfirrmann, M. Manz, K. Guilhot, J. Dietz, C. Panagiotidis, P. Spiess, B. Seifarth, W. Fabarius, A. Müller, M. Pagoni, M. Dimou, M. Dengler, J. Waller, C.F. Brümmendorf, T.H. Herbst, R. Burchert, A. Janβen, C. Goebeler, M.E. Jost, P.J. Hanzel, S. Schafhausen, P. Prange-Krex, G. Illmer, T. Janzen, V. Klausmann, M. Eckert, R. Büschel, G. Kiani, A. Hofmann, W.-K. Mahon, F.-X. Saussele, S.
- Abstract
Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5‰) were associated with a twofold higher risk of relapse. Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results: The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54% (95% confidence interval [CI], 46%-62%). ABCG2 expression (‰) was retained as the only significant variable (P =.02; hazard ratio, 1.04; 95% CI, 1.01-1.07) in multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P =.04). Patients with an ABCG2/GUSB transcript level >4.5‰ (n = 93) showed a 12-month TFR rate of 47% (95% CI, 37%-57%), whereas patients with low ABCG2 expression (≤4.5‰; n = 39) had a 12-month TFR rate of 72% (95% CI, 55%-82%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. © 2018 The Authors
- Published
- 2018
40. PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE
- Author
-
Minga, E., primary, Moysiadis, T., additional, Chatzikonstantinou, T., additional, Petropoulos, A., additional, Koulieris, E., additional, Iliakis, T., additional, Dimou, M., additional, Panagiotidis, P., additional, Anagnostopoulos, A., additional, Stamatopoulos, K., additional, Stavroyianni, N., additional, and Chatzidimitriou, A., additional
- Published
- 2019
- Full Text
- View/download PDF
41. PS1192 INITIAL REPORT OF A NILOTINIB DISCONTINUATION PROJECT WITH 54 GREEK CML PATIENTS FOLLOWED IN ACCORDANCE TO THE APPROVED DISCONTINUATION INDICATION OF THE DRUG
- Author
-
Dimou, M., primary, Roumelioti, M., additional, Touloumenidou, T., additional, Stefanou, A., additional, Staikou, E., additional, Iliakis, T., additional, Angelopoulou, M., additional, Kouraklis, A., additional, Symeonidis, A., additional, Adamopoulos, I., additional, Papalexandri, A., additional, and Panayiotidis, P., additional
- Published
- 2019
- Full Text
- View/download PDF
42. S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP
- Author
-
Pleyer, L., primary, Leisch, M., additional, Kouraklis, A., additional, Padron, E., additional, Maciejewski, J.P., additional, Xicoy Cirici, B., additional, Kaivers, J., additional, Ungerstedt, J., additional, Sonja, H., additional, Peristera, P., additional, Hunter, A., additional, Mora, E., additional, Geissler, K., additional, Dimou, M., additional, Jimenez Lorenzo, M.J., additional, Kiesl, D., additional, Vyniou, A.-N., additional, Patel, B.J., additional, Montserrat, A., additional, Valent, P., additional, Christoforos, R., additional, Bernal, T., additional, Galanopoulos, A., additional, Calabuig Munoz, M., additional, Bonadies, N., additional, Almeida, A., additional, Cermak, J., additional, Jerez, A., additional, Montoro, J., additional, Cortés, A., additional, Avendaño Pita, A., additional, Lopez Andrade, B., additional, Hellstroem-Lindberg, E., additional, Germing, U., additional, Sekeres, M., additional, List, A., additional, Symeonidis, A., additional, Sanz, G.F., additional, and Greil, R., additional
- Published
- 2019
- Full Text
- View/download PDF
43. PF693 PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY
- Author
-
Pontikoglou, C., primary, Kaliafentaki, V., additional, Stavroulaki, E., additional, Tzikoulis, V., additional, Kanellou, P., additional, Symeonidis, A., additional, Patrinos, A., additional, Kourakli, A., additional, Chatzilygeroudi, T., additional, Panayiotidis, P., additional, Viniou, N.-A., additional, Matzourani, M., additional, Dimou, M., additional, Galanopoulos, A., additional, Chondropoulos, S., additional, Roubakis, C., additional, Liapi, D., additional, Kolovou, A., additional, Tsirakis, G., additional, Anagnostopoulos, A., additional, Syrigou, A., additional, Gavriilaki, E., additional, Megalakaki, A., additional, Lampropoulou, P., additional, Vlachaki, E., additional, Christodoulou, I., additional, Papaioannou, M., additional, Gogou, V., additional, Bobola, M., additional, Giannouli, S., additional, Kotsianidis, I., additional, Vassilopoulos, G., additional, Protopappa, M., additional, Hatzimichael, E., additional, Zikos, P., additional, Chalkiadakis, G., additional, and Papadaki, H.A., additional
- Published
- 2019
- Full Text
- View/download PDF
44. PB2079 INCIDENCE OF MBL AT MDS DIAGNOSIS AND CLINICAL IMPLICATIONS
- Author
-
Pardalis, V., primary, Dimou, M., additional, Iliakis, T., additional, Bitsani, A., additional, Papaioannou, P., additional, Koudouna, A., additional, Kalyva, S., additional, Markopoulos, A., additional, Grafakos, I., additional, Kyrtsonis, M.-C., additional, and Panagiotidis, P., additional
- Published
- 2019
- Full Text
- View/download PDF
45. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens
- Author
-
Vassilakopoulos, T.P. Dimopoulou, M.N. Angelopoulou, M.K. Petevi, K. Pangalis, G.A. Moschogiannis, M. Dimou, M. Boutsikas, G. Kanellopoulos, A. Gainaru, G. Plata, E. Flevari, P. Koutsi, K. Papageorgiou, L. Telonis, V. Tsaftaridis, P. Sachanas, S. Yiakoumis, X. Tsirkinidis, P. Viniou, N.-A. Siakantaris, M.P. Variami, E. Kyrtsonis, M.-C. Meletis, J. Panayiotidis, P. Konstantopoulos, K.
- Subjects
musculoskeletal diseases - Abstract
Low absolute lymphocyte count (ALC) to absolute monocyte count (AMC) ratio (ALC/AMC) is an independent prognostic factor in Hodgkin lymphoma (HL), but different cutoffs (1.1, 1.5, and 2.9) have been applied. We aimed to validate the prognostic significance of ALC/AMC in 537 homogenously treated (doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalents 6 radiotherapy) classical HL patients at various cutoffs. The median ALC/AMC was 2.24 (0.44-20.50). The median AMC was 0.653 X 109/L (0.050-2.070). Lower ALC/ AMC was associated with established markers of adverse prognosis. In total, 477 (89%), 418 (78%), and 189 (35%) patients had an ALC/AMC ratio of $1.1, $1.5, and $2.9; respectively; 20% had monocytosis ($0.9 X 109/L).Ten-year time to progression (TTP) was 77% versus 55% for patients with ALC/AMC $1.1 and
- Published
- 2016
46. Disulfides with Anti-inflammatory Activity from the Brown Alga Dictyopteris membranacea
- Author
-
Dimou, M. Ioannou, E. Daskalaki, M.G. Tziveleka, L.A. Kampranis, S.C. Roussis, V.
- Abstract
Six new (1, 2, and 4-7) and two previously reported (3 and 8) disulfides, along with 4-butyl-2,6-cycloheptadienone, γ-tocopherol, and δ-tocopherol, were isolated from an organic extract of the brown alga Dictyopteris membranacea, collected at Gerolimenas Bay, Greece. The structure elucidation of the isolated natural products was based on analysis of their spectroscopic data. Compounds 1, 3-6, and 8 were evaluated for their antibacterial and anti-inflammatory activities. None of the compounds displayed antibacterial activity against two resistant strains of Staphylococcus aureus and one strain of Escherichia coli. In contrast, metabolite 5 was able to cause strong inhibition of NO production with an IC50 value of 3.8 μM using an LPS stimulation assay. © 2016 The American Chemical Society and American Society of Pharmacognosy.
- Published
- 2016
47. The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia
- Author
-
Sébastien, R., primary, Sticht, C., additional, Pfirrmann, M., additional, Nowak, D., additional, Fabarius, A., additional, Seifarth, W., additional, Spiess, B., additional, Panayiotidis, P., additional, Pagoni, M., additional, Dimou, M., additional, Dengler, J., additional, Waller, C.F., additional, Brümmendorf, T.H., additional, Burchert, A., additional, Freunek, G., additional, Hofmann, W-K., additional, Mahon, F-X., additional, and Saussele, S., additional
- Published
- 2017
- Full Text
- View/download PDF
48. Endophytic fungi residing in medicinal plants have the ability to produce the same or similar pharmacologically active secondary metabolites as their hosts
- Author
-
Venieraki, A., primary, Dimou, M., additional, and Katinakis, P., additional
- Published
- 2017
- Full Text
- View/download PDF
49. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
- Author
-
Moreno, C, Montillo, M, Panayiotidis, P, Dimou, M, Bloor, A, Dupuis, J, Schuh, A, Norin, S, Geisler, C, Hillmen, P, Doubek, M, Trněný, M, Obrtlikova, P, Laurenti, L, Stilgenbauer, S, Smolej, L, Ghia, P, Cymbalista, F, Jaeger, U, Stamatopoulos, K, Stavroyianni, N, Carrington, P, Zouabi, H, Leblond, V, Gomez Garcia JC, Rubio, M, Marasca, Roberto, Musuraca, G, Rigacci, L, Farina, L, Paolini, R, Pospisilova, S, Kimby, E, Bradley, C, and Montserrat, E.
- Subjects
Treatment ,Poor Prognosis ,Chronic Lymphocytic Leukemia ,Ofatumumab - Published
- 2015
50. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukemia
- Author
-
Moreno, C. Montillo, M. Panayiotidis, P. Dimou, M. Bloor, A. Dupuis, J. Schuh, A. Norin, S. Geisler, C. Hillmen, P. Doubek, M. Trněný, M. Obrtlikova, P. Laurenti, L. Stilgenbauer, S. Smolej, L. Ghia, P. Cymbalista, F. Jaeger, U. Stamatopoulos, K. Stavroyianni, N. Carrington, P. Zouabi, H. Leblond, V. Gomez-Garcia, J.C. Rubio, M. Marasca, R. Musuraca, G. Rigacci, L. Farina, L. Paolini, R. Pospisilova, S. Kimby, E. Bradley, C. Montserrat, E.
- Abstract
We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. Total number of patients was 103; median age was 65 years (range 39-85). Median number of prior lines of therapy was 4 (range 1-13), including, in most cases, rituximab-, fludarabine-and alemtuzumab-based regimens; 13 patients had been allografted. Of 113 adverse events, 28 (29%) were considered to be directly related to ofatumumab. Grade 3-4 toxicities included neutropenia (10%), thrombocytopenia (5%), anemia (3%), pneumonia (17%), and fever (3%). Two heavily pre-treated patients developed progressive multifocal leukoencephalopathy. On an intention-to-treat analysis, the overall response rate was 22% (3 complete response, 1 incomplete complete response). Median progression-free and overall survival times were 5 and 11 months, respectively. This study confirms in a daily-life setting the feasibility and acceptable toxicity of ofatumumab treatment in advanced chronic lymphocytic leukemia. The complete response rate, however, was low. Therefore, treatment with ofatumumab should be moved to earlier phases of the disease. Ideally, this should be done in combination with other agents, as recently approved for ofatumumab plus chlorambucil as front-line treatment for patients unfit for fludarabine. © 2015 Ferrata Storti Foundation.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.